Document:

www.EXFILE.com  888.775.4789   MATRITECH, INC.  FORM 8K == EXHIBIT 4.6

    EXHIBIT
      4.6

     

    AGREEMENT
      AND AMENDMENT OF CERTAIN OF THE 15% SECURED

    CONVERTIBLE
      PROMISSORY NOTES DATED JANUARY 13, 2006 AND DATED

     JANUARY
      22, 2007

    

    This
      Agreement and Amendment is executed and delivered on this 31st day of August
      2007 by and among Matritech, Inc. (the “Borrower”) and the
      undersigned holders of (i) certain 15% Secured Convertible Promissory Notes
      issued by the Borrower on January 13, 2006 (the “Series A
      Notes”) pursuant to the Securities Purchase Agreement, dated as of
      January 13, 2006, by and among the Borrower and the purchasers party thereto
      and
      previously amended on January 22, 2007, July 27, 2007 and August 30, 2007 (the
      “Series A Purchase Agreement”); and (ii) certain 15% Secured
      Convertible Promissory Notes issued by the Borrower on January 22, 2007 (the
      “Series B Notes”) pursuant to the Securities Purchase
      Agreement, dated as of January 22, 2007, by and among the Borrower and the
      purchasers party thereto and previously amended on July 27, 2007 and August
      30,
      2007 (the “Series B Purchase Agreement”).  The
      undersigned holders of the Series A Notes shall be referred to as the
“Series A Holders.”  The undersigned holders of the
      Series B Notes shall be referred to as the “Series B
Holders.”  All capitalized terms used in
      this Agreement and Amendment but not otherwise defined herein shall have the
      meanings ascribed to such terms in the Series A Purchase Agreement and the
      Series B Purchase Agreement, respectively.

    

    WHEREAS,
      the Borrower will enter into an Asset Purchase Agreement (the “Asset
      Purchase Agreement”), by and among Inverness Medical Innovations, Inc.
      (“Inverness”), Milano Acquisition Corp., and the Borrower,
      dated on or around the date hereof, under which the Borrower will agree to
      sell
      substantially all of its assets to Milano Acquisition Corp., in exchange for
      an
      initial payment of shares of Inverness common stock valued at approximately
      $36
      million (the “Inverness Shares”); and

    

    WHEREAS,
      after the closing under the Asset Purchase Agreement (the “Asset
      Purchase Closing”), the Borrower intends to resell the Inverness Shares
      under a Form S-3 registration statement as soon as reasonably practicable in
      order to repay the amounts owed under the Series A Notes and the Series B Notes
      and to satisfy the Borrower’s other obligations.

    

    NOW,
      THEREFORE, for good and valuable consideration, the receipt and legal
      sufficiency of which is hereby acknowledged, the parties agree as
      follows:

    

    1.           This
      Agreement and Amendment shall amend only the outstanding Series A Notes held
      by
      the undersigned Series A Holders and shall amend only the outstanding Series
      B
      Notes held by the undersigned Series B Holders.  No holder of a Series
      A Note or a Series B Note who is not a signatory to this Agreement and Amendment
      shall be bound by, or receive the benefits of, this Agreement and
      Amendment.  No holder of both Series A Notes and Series B Notes may be
      a signatory to this Agreement and Amendment except to the extent the Agreement
      and Amendment is signed by such holder in its capacity as a holder of both
      the
      Series A Notes and the Series B Notes.

     

     

     

     

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    2.           Each
      of the undersigned holders of Series A Notes and Series B Notes hereby agrees
      to
      not issue a Default Notice (as defined in the Series A Notes and the Series
      B
      Notes) for (a) any Event of Default occurring under Article VI.A(viii)(a) with
      respect to the consummation of the Asset Purchase Closing, (b) any Event of
      Default occurring under Article VI.A(i) with respect to non-payment of any
      Principal, Interest or other payment due or (c) any Event of Default occurring
      under Article VI.A(viii)(c) with respect to any failure to pay the holders
      of,
      or allowing an Event of Default to exist under, the Series A or Series B Notes
      or the Borrower’s Series A Convertible Preferred Stock until ten (10) business
      days after the later of (x) a Registration Statement on Form S-3 which registers
      the Inverness Shares for resale by the Borrower is declared effective by the
      Securities and Exchange Commission or (y) the date of the Asset Purchase Closing
      (collectively the “Payment Trigger Events”); provided, however,
      that the Holder need not forbear on issuance of a Default Notice for more than
      ninety (90) days after the date of the Asset Purchase Closing.  If any
      of the undersigned holders of the Series A Notes or the Series B Notes delivers
      a Default Notice to the Borrower before the later of the Payment Trigger Events,
      the Default Notice shall not be considered received by the Borrower until the
      later of such Payment Trigger Events.

    

    3.           In
      consideration for the agreement of the undersigned Series A Holders to forbear
      an issuance of a Default Notice and triggering a payment of the Default Amount
      (as defined in the Series A Notes), the Borrower agrees that, notwithstanding
      the date of payment in full to the undersigned Series A Holders of amounts
      due
      to them under the Series A Notes, the Borrower shall be obligated to pay the
      prepayment premium set forth in Article I.C of the Series A Notes as part of
      the
      payment in full due to the undersigned Series A Holders on the Series A Notes;
      provided, however, that the undersigned Series A Holders shall
      not under any circumstances become entitled to receive both the Default Amount
      and the prepayment premium.

    

    4.           In
      consideration for the agreement of the undersigned Series B Holders to forbear
      on issuance of a Default Notice and triggering a payment of the Default Amount
      (as defined in the Series B Notes), the Borrower agrees that, notwithstanding
      the date of payment in full to the undersigned Series B Holders of amounts
      due
      to them under the Series B Notes, the Borrower shall be obligated to pay the
      prepayment premium set forth in Article I.C of the Series B Notes as part of
      the
      payment in full due to the undersigned Series B Holders on the Series B Notes;
      provided, however, that the undersigned Series B Holders shall
      not under any circumstances become entitled to receive both the Default Amount
      and the prepayment premium.

    

    5.  
In
      further consideration for the agreement of the undersigned Series B Holders
      to
      forbear on issuance of a Default Notice and triggering a payment of the Default
      Amount (as defined in the Series B Notes), the Borrower and the undersigned
      Series B Holders agree that:

    

    (a)           the
      last clause of Article VI.B of the Series B Notes held by the undersigned Series
      B Holders is hereby deleted in its entirety and replaced with the
      following:

    

    “
‘R’
means
      one hundred and twenty-five
      percent (125%)”.

     

     

     

     

     

     

     

     

     

     

    
 

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    (b)            a
      new Article VI.D. is added to the Series B Notes held by the undersigned Series
      B Holders as follows:

    

    “D.
      Accord with Prepayment Premium Provisions.  For the avoidance of
      doubt, if an Event of Default (as defined herein) were to occur and the Borrower
      were then to be required to pay the Holder the Default Amount, then the Borrower
      shall be relieved of any obligation to pay the Holder the Prepayment Premium
      described in Article I.C of this Note.”

     

    6.           Except
      as expressly set forth herein, (a) the original terms and conditions of the
      Series A Notes, as previously amended on January 22, 2007 and July 27, 2007,
      shall remain in full force and effect; (b) this Agreement and Amendment shall
      not be deemed to be a waiver, amendment or modification of, or consent to or
      departure from, any provision of the Series A Notes or to be a waiver of any
      Event of Default whether arising before or after the date hereof as a result
      of
      the transactions contemplated hereby; and (c) this Agreement and Amendment
      shall
      not preclude the future exercise of any right, remedy, power or privilege
      available to the undersigned Series A Holders whether under the Series A Notes
      or otherwise, and shall not be construed or deemed to be a satisfaction,
      novation, cure, modification, amendment or release of the Series A
      Notes.

    

    7.           Except
      as expressly set forth herein, (a) the original terms and conditions of the
      Series B Notes, as previously amended on July 27, 2007, shall remain in full
      force and effect; (b) this Agreement and Amendment shall not be deemed to be
      a
      waiver, amendment or modification of, or consent to or departure from, any
      provision of the Series B Notes or to be a waiver of any Event of Default
      whether arising before or after the date hereof as a result of the transactions
      contemplated hereby; and (c) this Agreement and Amendment shall not preclude
      the
      future exercise of any right, remedy, power or privilege available to the
      undersigned Series B Holders whether under the Series B Notes or otherwise,
      and
      shall not be construed or deemed to be a satisfaction, novation, cure,
      modification, amendment or release of the Series B Notes.

    

    8.           This
      Agreement and Amendment (a) constitutes the entire understanding of the parties
      with respect to the subject matter hereof, and any other prior agreements,
      whether written or oral, with respect hereto or thereto are expressly superseded
      hereby; (b) shall be governed by and construed in accordance with the laws
      of
      the State of Delaware without regard to principles of conflicts of laws; and
      (c)
      shall be binding upon and inure to the benefit of the successors and assigns
      of
      the Borrower and the undersigned Series A Holders and the undersigned Series
      B
      Holders.

    

    9.           This
      Agreement and Amendment may be executed in multiple counterparts, each of which
      shall be deemed an original (but as to each undersigned Holder such counterparts
      shall constitute one and the same instrument), and by facsimile transmission,
      which facsimile signatures shall be considered original executed
      counterparts.

    

    

    [Remainder
      of Page Intentionally Left Blank]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the undersigned Series A Holders
      and the Series B Holders have caused this Agreement and Amendment to be executed
      as of the day first above written.

     

    
 

    Borrower:

    

    Matritech,
      Inc.

    

    By:
/s/
      Stephen D.
      Chubb              

    Name:    Stephen
      D. Chubb

    Title:      Chief
      Executive Officer

    

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the undersigned Series A Holders
      and Series B Holders have caused this Agreement and Amendment to be executed
      as
      of the day first above written.

     

    
 

    
      	
            	
               

            	
              Holders:

            

    

    

    SDS
      Capital Group SPC, Ltd., on behalf of its Class D
      segregated portfolio

    

    

    
      	
            	
               

            	
              By:
                /s/ Steve
                Derby_____________________

            

    

    
      	
               

            	
              Name:        Steve
                Derby

            

    

    
      	
               

            	
              Title:

            	
              Director

            

    

    
      	
            	
               

            	
              Series
                A Notes Held: $1,323,333 principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $1,140,000 principal

            

    

    

    

    
      	
               

            	
              ProMed
                Partners, L.P.

            

    

    

    

    
      	
            	
               

            	
              By:
                /s/ David B.
                Musket__________________

            

    

    
      	
               

            	
              Name:

            	
              David
                B. Musket

            

    

    
      	
               

            	
              Title:

            	
              Managing
                Director

            

    

    
      	
            	
               

            	
              Series
                A Notes Held: $131,476 principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $320,399 principal

            

    

    

    

    
      	
               

            	
              ProMed
                Partners II, L.P.

            

    

    

    

    
      	
            	
               

            	
              By:
                /s/ David B.
                Musket___________________

            

    

    
      	
               

            	
              Name:

            	
              David
                B. Musket

            

    

    
      	
               

            	
              Title:

            	
              Managing
                Director

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $16,816 principal

            

    

    

    

    
      	
               

            	
              ProMed
                Offshore Fund, Ltd.

            

    

    

    

    
      	
            	
               

            	
              By:
                /s/ David B.
                Musket____________________

            

    

    
      	
               

            	
              Name:

            	
              David
                B. Musket

            

    

    
      	
               

            	
              Title:

            	
              Managing
                Director

            

    

    
      	
            	
               

            	
              Series
                A Notes Held: $22,539 principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $48,072 principal

            

    

    

     

     

    
 

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Borrower and the undersigned Series A Holders
      and Series B Holders have caused this Agreement and Amendment to be executed
      as
      of the day first above written.

     

    
 

    
      	
               

            	
              ProMed
                Offshore Fund II, Ltd.

            

    

    

    

    
      	
            	
               

            	
              By:
                /s/ David B.
                Musket____________________

            

    

    
      	
               

            	
              Name:        David
                B. Musket

            

    

    
      	
               

            	
              Title:

            	
              Managing
                Director

            

    

    
      	
            	
               

            	
              Series
                A Notes Held: $835,569
                principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $414,713 principal

            

    

    

    

    
      	
               

            	
              David
                B. Musket,
                Individually

            

    

    

    

    
      	
            	
               

            	
              /s/
                David B.
                Musket_______________________

            

    

    
      	
            	
               

            	
              Series
                A Notes Held:
                $106,875 principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held:
                $250,000
                principal

            

    

    

    

    
      	
               

            	
              H&Q
                Life Science Investors

            

    

    

    

    
      	
            	
               

            	
              By:
                /s/ Daniel R.
                Omstead__________________

            

    

    
      	
               

            	
              Name:

            	
              Daniel
                R. Omstead

            

    

    
      	
               

            	
              Title:

            	
              President

            

    

    
      	
            	
               

            	
              Series
                A Notes Held: $1,583,333 principal

            

    

    
      	
            	
               

            	
              Series
                B Notes Held: $1,000,000 principal

            

    

     

     

    
 

    The
      term
      H&Q Life Sciences Investors is the designation of the Trustees for the time
      being under a Declaration of Trust dated February 20, 1992, as amended, and
      all
      persons dealing with H&Q Life Sciences Investors must look solely to the
      trust property for the enforcement of any claims against H&Q Life Sciences
      Investors, and neither the Trustees, officers nor shareholders assume any
      personal liability for the obligations entered into on behalf of H&Q Life
      Sciences Investors.Exhibit
            10.11

            

            SECURITIES
            PURCHASE AGREEMENT

            

            
                    
            SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of
            August 31, 2007, by and among Amish Naturals, Inc., a Nevada corporation, with
            headquarters located at 6399 State Route 83, Holmesville, Ohio 44633
            (the “Company”), and the investors listed on the Schedule of
            Buyers attached hereto (individually, a “Buyer” and collectively,
            the “Buyers”).

            

            
                    
            WHEREAS:

            

            
                A.           
            The Company and each Buyer is executing and delivering this Agreement in reliance upon
            the exemption from securities registration afforded by Section 4(2) of the Securities
            Act of 1933, as amended (the “1933 Act”), and Rule 506 of Regulation
            D (“Regulation D”) as promulgated by the United States
            Securities and Exchange Commission (the “SEC”) under the 1933
            Act.

            

            
                B.           
            The Company has authorized a new series of senior secured convertible notes of the
            Company which notes shall be convertible into the Company’s common stock, par
            value $0.001 per share (the “Common Stock”), in accordance with
            the terms of the Notes (as defined below).

            

            
                C.           
            Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and
            conditions stated in this Agreement, (i) that aggregate principal amount of the Notes,
            in substantially the form attached hereto as Exhibit A (the
            “Notes”), set forth opposite such Buyer’s name in column (3)
            on the Schedule of Buyers attached hereto (which aggregate amount for all Buyers shall
            be $6,000,000) (as converted, collectively, the “Conversion
            Shares”), (ii) warrants, in substantially the form attached hereto as
            Exhibit B (the “Series AWarrants”), to acquire that
            number of shares of Common Stock set forth opposite such Buyer’s name in column
            (4) on the Schedule of Buyers, (iii) warrants, in substantially the form attached
            hereto as Exhibit B (the “Series BWarrants”), to
            acquire that number of shares of Common Stock set forth opposite such Buyer’s
            name in column (5) on the Schedule of Buyers, (iv) warrants, in substantially the form
            attached hereto as Exhibit B (the “Series CWarrants”),
            to acquire that number of shares of Common Stock set forth opposite such Buyer’s
            name in column (6) on the Schedule of Buyers, and (v) warrants in substantially the
            form attached hereto as Exhibit C (the “Series D Warrants”,
            and collectively with the Series A Warrants, Series B Warrants and Series C Warrants,
            the “Warrants”) to acquire that number of shares of Common Stock set
            forth opposite such Buyer’s name in column (7) on the Schedule of Buyers (as
            exercised, collectively, the “Warrant Shares”).

            

            
                D.           
            The Notes bear interest, which at the option of the Company, subject to certain
            conditions, may be paid in shares of Common Stock (the “Interest
            Shares”).

            
            
            

            
            

            

            
                    E.           
            Contemporaneously with the execution and delivery of this Agreement, the parties hereto
            are executing and delivering a Registration Rights Agreement, substantially in the form
            attached hereto as Exhibit D (the “Registration Rights
            Agreement”), pursuant to which the Company has agreed to provide certain
            registration rights with respect to the Registrable Securities (as defined in the
            Registration Rights Agreement) under the 1933 Act and the rules and regulations
            promulgated thereunder, and applicable state securities laws.

            

            
                    F.           
            The Notes, the Conversion Shares, the Interest Shares, the Warrants and the Warrant
            Shares collectively are referred to herein as the
            “Securities”.

            

            
                    G.           
            The Notes will rank senior to all outstanding and future indebtedness of the Company,
            other than Permitted Senior Indebtedness (as defined in the Notes), and will be secured
            by a first priority perfected security interest in all of the assets of the Company and
            the stock, equity interests and assets of each of the Company’s subsidiaries, as
            evidenced by (i) a pledge agreement, in the form attached hereto as Exhibit E
            (as amended or modified from time to time in accordance with its terms, the
            “Pledge Agreement”), (ii) a security agreement, in the form attached
            hereto as Exhibit F (as amended or modified from time to time in accordance with
            its terms, the “Security Agreement”), and (iii) the guaranties of
            the subsidiaries of the Company in the form attached hereto as Exhibit G (as
            amended or modified from time to time in accordance with its terms, the
            “Guaranty” and, together with the Pledge Agreement, the Security Agreement
            and any ancillary documents related thereto, collectively the “Security
            Documents”).

            

            
                    
            NOW, THEREFORE, the Company and each Buyer hereby agree as follows:

            

            
                    1.           
            PURCHASE AND SALE OF NOTES AND WARRANTS.

            

                
                      (a)           
            Purchase of Notes and Warrants. Subject to the satisfaction (or waiver) of the
            conditions set forth in Sections 6 and 7 below, the Company shall issue and sell to
            each Buyer, and each Buyer severally, but not jointly, agrees to purchase from the
            Company on the Closing Date (as defined below), (v) a principal amount of Notes as is
            set forth opposite such Buyer’s name in column (3) on the Schedule of Buyers, (w)
            Series A Warrants to acquire that number of Warrant Shares as is set forth opposite
            such Buyer’s name in column (4) on the Schedule of Buyers; (x) Series B Warrants
            to acquire that number of Warrant Shares as is set forth opposite such Buyer’s
            name in column (5) on the Schedule of Buyers, (y) Series C Warrants to acquire that
            number of Warrant Shares as is set forth opposite such Buyer’s name in column (6)
            on the Schedule of Buyers, and (z) Series D Warrants to acquire that number of Warrant
            Shares as is set forth opposite such Buyer’s name in column (7) on the Schedule
            of Buyers (the “Closing”).

            

                
                      (b)           
            Closing. The date and time of the Closing (the “Closing Date”)
            shall be 10:00 a.m., New York City time, on the date hereof (or such later date as is
            mutually agreed to by the Company and each Buyer) after notification of satisfaction
            (or waiver) of the conditions to the Closing set forth in Sections 6 and 7 below at the
            offices of Schulte Roth & Zabel LLP, 919 Third Avenue, New York, New York
            10022.

            

                
                      (c)           
            Purchase Price.

            

                
                      
                      (i)           
            The aggregate purchase price for the Notes and the Warrants to be purchased by each
            such Buyer at the Closing (the “Purchase Price”) shall be the amount
            set forth opposite each Buyer’s name in column (8) of the Schedule of Buyers.
            Each Buyer shall pay $1,000 for each $1,000 of principal amount of Notes and related
            Warrants to be purchased by such Buyer at the Closing.

            

            -2-

            
            
            

            
            

            

                
                      (d)           
            Form of Payment. On the Closing Date, (i) each Buyer shall pay its Purchase Price
            to the Company for the Notes and the Warrants to be issued and sold to such Buyer at
            the Closing, by wire transfer of immediately available funds in accordance with the
            Company’s written wire instructions and (ii) the Company shall deliver to
            each Buyer the Notes (allocated in the principal amounts as such Buyer shall request)
            which such Buyer is then purchasing hereunder along with the Warrants (allocated in the
            amounts as such Buyer shall request) which such Buyer is purchasing, in each case duly
            executed on behalf of the Company and registered in the name of such Buyer or its
            designee.

            

            
                    2.    
            BUYER’S REPRESENTATIONS AND WARRANTIES. Each Buyer, severally and not
            jointly, represents and warrants with respect to only itself that:

            

                
                      (a)           
            No Public Sale or Distribution. Such Buyer is (i) acquiring the Notes and the
            Warrants and (ii) upon conversion of the Notes and exercise of the Warrants (other than
            pursuant to a Cashless Exercise (as defined in the Warrants)) will acquire the
            Conversion Shares issuable upon conversion of the Notes and the Warrant Shares issuable
            upon exercise of the Warrants, for its own account and not with a view towards, or for
            resale in connection with, the public sale or distribution thereof, except pursuant to
            sales registered or exempted under the 1933 Act; provided, however, that
            by making the representations herein, such Buyer does not agree to hold any of the
            Securities for any minimum or other specific term and reserves the right to dispose of
            the Securities at any time in accordance with or pursuant to a registration statement
            or an exemption under the 1933 Act. Such Buyer is acquiring the Securities hereunder in
            the ordinary course of its business. Such Buyer does not presently have any agreement
            or understanding, directly or indirectly, with any Person to distribute any of the
            Securities.

            

                
                      (b)           
            Accredited Investor Status. Such Buyer is an “accredited investor” as
            that term is defined in Rule 501(a) of Regulation D.

            

                
                      (c)           
            Reliance on Exemptions. Such Buyer understands that the Securities are being
            offered and sold to it in reliance on specific exemptions from the registration
            requirements of United States federal and state securities laws and that the Company is
            relying in part upon the truth and accuracy of, and such Buyer’s compliance with,
            the representations, warranties, agreements, acknowledgments and understandings of such
            Buyer set forth herein in order to determine the availability of such exemptions and
            the eligibility of such Buyer to acquire the Securities.

            

                
                      (d)           
            Information. Such Buyer and its advisors, if any, have been furnished with all
            materials relating to the business, finances and operations of the Company and
            materials relating to the offer and sale of the Securities which have been requested by
            such Buyer. Such Buyer and its advisors, if any, have been afforded the opportunity to
            ask questions of the Company. Neither such inquiries nor any other due diligence
            investigations conducted by such Buyer or its advisors, if any, or its representatives
            shall modify, amend or affect such Buyer’s right to rely on the Company’s
            representations and warranties contained herein. Such Buyer understands that its
            investment in the Securities involves a high degree of risk. Such Buyer has sought such
            accounting, legal and tax advice as it has considered necessary to make an informed
            investment decision with respect to its acquisition of the Securities.

            

            -3-

            
            
            

            
            

            

                
                      (e)           
            No Governmental Review. Such Buyer understands that no United States federal or
            state agency or any other government or governmental agency has passed on or made any
            recommendation or endorsement of the Securities or the fairness or suitability of the
            investment in the Securities nor have such authorities passed upon or endorsed the
            merits of the offering of the Securities.

            

                
                      (f)           
            Transfer or Resale. Such Buyer understands that except as provided in the
            Registration Rights Agreement: (i) the Securities have not been and are not being
            registered under the 1933 Act or any state securities laws, and may not be offered for
            sale, sold, assigned or transferred unless (A) subsequently registered thereunder, (B)
            such Buyer shall have delivered to the Company an opinion of counsel, in a generally
            acceptable form, to the effect that such Securities to be sold, assigned or transferred
            may be sold, assigned or transferred pursuant to an exemption from such registration,
            or (C) such Buyer provides the Company with reasonable assurance that such Securities
            can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated
            under the 1933 Act, as amended, (or a successor rule thereto) (collectively,
            “Rule 144”); (ii) any sale of the Securities made in reliance on
            Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule
            144 is not applicable, any resale of the Securities under circumstances in which the
            seller (or the Person (as defined in Section 3(s)) through whom the sale is made) may
            be deemed to be an underwriter (as that term is defined in the 1933 Act) may require
            compliance with some other exemption under the 1933 Act or the rules and regulations of
            the SEC thereunder; and (iii) neither the Company nor any other Person is under any
            obligation to register the Securities under the 1933 Act or any state securities laws
            or to comply with the terms and conditions of any exemption thereunder. The Securities
            may be pledged in connection with a bona fide margin account or other loan or financing
            arrangement secured by the Securities and such pledge of Securities shall not be deemed
            to be a transfer, sale or assignment of the Securities hereunder, and no Buyer
            effecting a pledge of Securities shall be required to provide the Company with any
            notice thereof or otherwise make any delivery to the Company pursuant to this Agreement
            or any other Transaction Document (as defined in Section 3(b)), including, without
            limitation, this Section 2(f).

            

                
                      (g)           
            Legends. Such Buyer understands that the certificates or other instruments
            representing the Notes and the Warrants and, until such time as the resale of the
            Conversion Shares and the Warrant Shares have been registered under the 1933 Act as
            contemplated by the Registration Rights Agreement, the stock certificates representing
            the Conversion Shares and the Warrant Shares, except as set forth below, shall bear any
            legend as required by the “blue sky” laws of any state and a restrictive
            legend in substantially the following form (and a stop-transfer order may be placed
            against transfer of such stock certificates):

            

            	 	
                    [NEITHER THE
                    ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE
                    SECURITIES INTO WHICH THESE SECURITIES ARE
                    [CONVERTIBLE][EXERCISABLE]HAVE BEEN][THE SECURITIES
                    REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE
                    SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
                    SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN
                    THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
                    THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL, IN A
                    GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR
                    (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT.
                    NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
                    A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY
                    THE SECURITIES. 

            

            

            -4-

            
            
            

            
            

            

            The legend set forth above shall
            be removed and the Company shall issue a certificate without such legend to the holder
            of the Securities upon which it is stamped or issue to such holder by electronic
            delivery at the applicable balance account at DTC (as defined below), unless otherwise
            required by state securities laws, (i) such Securities are registered for resale under
            the 1933 Act, (ii) in connection with a sale, assignment or other transfer, such holder
            provides the Company with an opinion of counsel, in a generally acceptable form, to the
            effect that such sale, assignment or transfer of the Securities may be made without
            registration under the applicable requirements of the 1933 Act, or (iii) such holder
            provides the Company with reasonable assurance that the Securities can be sold,
            assigned or transferred pursuant to Rule 144 or Rule 144A.

            

                
                      (h)           
            Validity; Enforcement. This Agreement, the Registration Rights Agreement and the
            Security Documents to which such Buyer is a party have been duly and validly
            authorized, executed and delivered on behalf of such Buyer and shall constitute the
            legal, valid and binding obligations of such Buyer enforceable against such Buyer in
            accordance with their respective terms, except as such enforceability may be limited by
            general principles of equity or to applicable bankruptcy, insolvency, reorganization,
            moratorium, liquidation and other similar laws relating to, or affecting generally, the
            enforcement of applicable creditors’ rights and remedies.

            

                
                      (i)           
            No Conflicts. The execution, delivery and performance by such Buyer of this
            Agreement, the Registration Rights Agreement and the Security Documents to which such
            Buyer is a party and the consummation by such Buyer of the transactions contemplated
            hereby and thereby will not (i) result in a violation of the organizational documents
            of such Buyer or (ii) conflict with, or constitute a default (or an event which with
            notice or lapse of time or both would become a default) under, or give to others any
            rights of termination, amendment, acceleration or cancellation of, any agreement,
            indenture or instrument to which such Buyer is a party, or (iii) result in a violation
            of any law, rule, regulation, order, judgment or decree (including federal and state
            securities laws) applicable to such Buyer, except in the case of clauses (ii) and (iii)
            above, for such conflicts, defaults, rights or violations which would not, individually
            or in the aggregate, reasonably be expected to have a material adverse effect on the
            ability of such Buyer to perform its obligations hereunder.

            

            -5-

            
            
            

            
            

            

                
                      (j)           
            Residency. Such Buyer is a resident of that jurisdiction specified below its
            address on the Schedule of Buyers.

            

            
                    
            3.    REPRESENTATIONS AND WARRANTIES OF THE
            COMPANY.

            

            
                    
                   The Company represents and warrants to each
            of the Buyers that:

            

                
                      (a)       
            Organization and Qualification. Each of the Company and its
            “Subsidiaries” (which for purposes of this Agreement means any
            entity in which the Company, directly or indirectly, owns any of the capital stock or
            holds an equity or similar interest) are entities duly organized and validly existing
            in good standing under the laws of the jurisdiction in which they are formed, and have
            the requisite power and authorization to own their properties and to carry on their
            business as now being conducted. Each of the Company and its Subsidiaries is duly
            qualified as a foreign entity to do business and is in good standing in every
            jurisdiction in which its ownership of property or the nature of the business conducted
            by it makes such qualification necessary, except to the extent that the failure to be
            so qualified or be in good standing would not have a Material Adverse Effect. As used
            in this Agreement, “Material Adverse Effect” means any material
            adverse effect on the business, properties, assets, operations, results of operations,
            condition (financial or otherwise) or prospects of the Company and its Subsidiaries,
            taken as a whole, or on the transactions contemplated hereby and the other Transaction
            Documents or by the agreements and instruments to be entered into in connection
            herewith or therewith, or on the authority or ability of the Company to perform its
            obligations under the Transaction Documents (as defined below). The Company has no
            Subsidiaries except as set forth on Schedule 3(a).

            

                
                      (b)       
            Authorization; Enforcement; Validity. The Company has the requisite power and
            authority to enter into and perform its obligations under this Agreement, the Notes,
            the Registration Rights Agreement, the Security Documents, each of the Lock-Up
            Agreements (as defined below), the Irrevocable Transfer Agent Instructions (as defined
            in Section 5(b)), the Warrants, and each of the other agreements entered into by the
            parties hereto in connection with the transactions contemplated by this Agreement
            (collectively, the “Transaction Documents”) and to issue the
            Securities in accordance with the terms hereof and thereof. The execution and delivery
            of the Transaction Documents by the Company and the consummation by the Company of the
            transactions contemplated hereby and thereby, including, without limitation, the
            issuance of the Notes and the Warrants, the reservation for issuance and the issuance
            of the Conversion Sharesissuable upon conversion of the Notes, the reservation for
            issuance and issuance of Warrant Shares issuable upon exercise of the Warrants, the
            reservation for issuance and issuance of Interest Shares, if any, and the granting of a
            security interest in the Collateral (as defined in the Security Documents) have been
            duly authorized by the Company’s Board of Directors and (other than (i) the
            filing of appropriate UCC financing statements with the appropriate states and other
            authorities pursuant to the Security Agreement, and (ii) the filing with the SEC of one
            or more Registration Statements in accordance with the requirements of the Registration
            Rights Agreement) no further filing, consent, or authorization is required by the
            Company, its Board of Directors or its stockholders. This Agreement and the other
            Transaction Documents of even date herewith have been duly executed and delivered by
            the Company, and constitute the legal, valid and binding obligations of the Company,
            enforceable against the Company in accordance with their respective terms, except as
            such enforceability may be limited by general principles of equity or applicable
            bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws
            relating to, or affecting generally, the enforcement of applicable creditors’
            rights and remedies.

            

            -6-

            
            
            

            
            

            

                
                      (c)       
            Issuance of Securities. The issuance of the Notes and the Warrants are duly
            authorized and are free from all taxes, liens and charges with respect to the issue
            thereof. As of the applicable Closing, a number of shares of Common Stock shall have
            been duly authorized and reserved for issuance which equals or exceeds 130% of the
            aggregate of the maximum number of shares of Common Stock (i) issuable upon conversion
            of the Notes, (ii) as Interest Shares pursuant to the terms of the Notes and (iii) upon
            exercise of the Warrants (in the case of clauses (i) and (iii), without taking into
            account any limitations on the Conversion of the Notes or exercise of the Warrants set
            forth in the Notes and Warrants, respectively). Upon conversion or payment in
            accordance with the Notes or exercise in accordance with the Warrants, as the case may
            be, the Conversion Shares, the Interest Shares and the Warrant Shares, respectively,
            will be validly issued, fully paid and nonassessable and free from all preemptive or
            similar rights, taxes, liens and charges with respect to the issue thereof, with the
            holders being entitled to all rights accorded to a holder of Common Stock. The offer
            and issuance by the Company of the Securities is exempt from registration under the
            1933 Act.

            

                
                      (d)       
            No Conflicts. The execution, delivery and performance of the Transaction Documents
            by the Company and the consummation by the Company of the transactions contemplated
            hereby and thereby (including, without limitation, the issuance of the Notes and the
            Warrants, the granting of a security interest in the Collateral and reservation for
            issuance and issuance of the Conversion Shares, the Interest Shares and the Warrant
            Shares) will not (i) result in a violation of any certificate of incorporation,
            certificate of formation, any certificate of designations or other constituent
            documents of the Company or any of its Subsidiaries, any capital stock of the Company
            or any of its Subsidiaries or the bylaws of the Company or any of its Subsidiaries or
            (ii) conflict with, or constitute a default (or an event which with notice or lapse of
            time or both would become a default) in any respect under, or give to others any rights
            of termination, amendment, acceleration or cancellation of, any agreement, indenture or
            instrument to which the Company or any of its Subsidiaries is a party, or (iii) result
            in a violation of any law, rule, regulation, order, judgment or decree (including
            foreign, federal and state securities laws and regulations and the rules and
            regulations The OTC Bulletin Board (the “Principal Market”))
            applicable to the Company or any of its Subsidiaries or by which any property or asset
            of the Company or any of its Subsidiaries is bound or affected.

            

                
                      (e)       
            Consents. Neither the Company nor any of its Subsidiaries is required to obtain any
            consent, authorization or order of, or make any filing or registration with, any court,
            governmental agency or any regulatory or self-regulatory agency or any other Person in
            order for it to execute, deliver or perform any of its obligations under or
            contemplated by the Transaction Documents, in each case in accordance with the terms
            hereof or thereof. All consents, authorizations, orders, filings and registrations
            which the Company is required to obtain pursuant to the preceding sentence have been
            obtained or effected on or prior to the Closing Date, and the Company and its
            Subsidiaries are unaware of any facts or circumstances which might prevent the Company
            from obtaining or effecting any of the registration, application or filings pursuant to
            the preceding sentence. The Company is not in violation of the listing requirements of
            the Principal Market and has no knowledge of any facts which would reasonably lead to
            delisting or suspension of the Common Stock in the foreseeable future.

            

            -7-

            
            
            

            
            

            

                
                      (f)       
            Acknowledgment Regarding Buyer’s Purchase of Securities. The Company
            acknowledges and agrees that each Buyer is acting solely in the capacity of arm’s
            length purchaser with respect to the Transaction Documents and the transactions
            contemplated hereby and thereby and that no Buyer is (i) an officer or director of the
            Company, (ii) an “affiliate” of the Company or any of its Subsidiaries (as
            defined in Rule 144) or (iii) to the knowledge of the Company, a “beneficial
            owner” of more than 10% of the shares of Common Stock (as defined for purposes of
            Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “1934
            Act”)). The Company further acknowledges that no Buyer is acting as a
            financial advisor or fiduciary of the Company or any of its Subsidiaries (or in any
            similar capacity) with respect to the Transaction Documents and the transactions
            contemplated hereby and thereby, and any advice given by a Buyer or any of its
            representatives or agents in connection with the Transaction Documents and the
            transactions contemplated hereby and thereby is merely incidental to such Buyer’s
            purchase of the Securities. The Company further represents to each Buyer that the
            Company’s decision to enter into the Transaction Documents has been based solely
            on the independent evaluation by the Company and its representatives.

            

                
                      (g)       
            No General Solicitation; Placement Agent’s Fees. Neither the Company, nor any
            of its Subsidiaries or affiliates, nor any Person acting on its or their behalf, has
            engaged in any form of general solicitation or general advertising (within the meaning
            of Regulation D) in connection with the offer or sale of the Securities. The Company
            shall be responsible for the payment of any placement agent’s fees, financial
            advisory fees, or brokers’ commissions (other than for persons engaged by any
            Buyer or its investment advisor) relating to or arising out of the transactions
            contemplated hereby. The Company shall pay, and hold each Buyer harmless against, any
            liability, loss or expense (including, without limitation, attorney’s fees and
            out-of-pocket expenses) arising in connection with any such claim. The Company
            acknowledges that it has engaged Wharton Capital as placement agent (the
            “Placement Agent”) in connection with the sale of the Securities.
            Other than the Placement Agent, the Company has not engaged any placement agent or
            other agent in connection with the sale of the Securities.

            

                
                      (h)       
            No Integrated Offering. None of the Company, its Subsidiaries, any of their
            affiliates, and any Person acting on their behalf has, directly or indirectly, made any
            offers or sales of any security or solicited any offers to buy any security, under
            circumstances that would require registration of any of the Securities under the 1933
            Act or cause this offering of the Securities to be integrated with prior offerings by
            the Company for purposes of the 1933 Act or any applicable stockholder approval
            provisions, including, without limitation, under the rules and regulations of any
            exchange or automated quotation system on which any of the securities of the Company
            are listed or designated. None of the Company, its Subsidiaries, their affiliates and
            any Person acting on their behalf will take any action or steps referred to in the
            preceding sentence that would require registration of any of the Securities under the
            1933 Act or cause the offering of the Securities to be integrated with other
            offerings.

            

                
                      (i)       
            Dilutive Effect. The Company understands and acknowledges that the number of
            Conversion Shares issuable upon conversion of the Notes and the Warrant Shares issuable
            upon exercise of the Warrants will increase in certain circumstances. The Company
            further acknowledges that its obligation to issue Conversion Shares upon conversion of
            the Notes in accordance with this Agreement and the Notes and its obligation to issue
            the Warrant Shares upon exercise of the Warrants in accordance with this Agreement and
            the Warrants is, in each case, is absolute and unconditional regardless of the dilutive
            effect that such issuance may have on the ownership interests of other stockholders of
            the Company.

            

            -8-

            
            
            

            
            

            

                
                      (j)       
            Application of Takeover Protections; Rights Agreement. The Company and its board of
            directors have taken all necessary action, if any, in order to render inapplicable any
            control share acquisition, business combination, poison pill (including any
            distribution under a rights agreement) or other similar anti-takeover provision under
            the Articles of Incorporation or the laws of the jurisdiction of its formation which is
            or could become applicable to any Buyer as a result of the transactions contemplated by
            this Agreement, including, without limitation, the Company’s issuance of the
            Securities and any Buyer’s ownership of the Securities. The Company has not
            adopted a stockholder rights plan or similar arrangement relating to accumulations of
            beneficial ownership of Common Stock or a change in control of the
            Company.

            

                
                      (k)       
            SEC Documents; Financial Statements. Except as disclosed in Schedule 3(k),
            during the two (2) years prior to the date hereof, the Company has filed all reports,
            schedules, forms, statements and other documents required to be filed by it with the
            SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing filed
            prior to the date hereof and all exhibits included therein and financial statements,
            notes and schedules thereto and documents incorporated by reference therein being
            hereinafter referred to as the “SEC Documents”). The Company has
            delivered to the Buyers or their respective representatives true, correct and complete
            copies of the SEC Documents not available on the EDGAR system. As of their respective
            dates, the SEC Documents complied in all material respects with the requirements of the
            1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to
            the SEC Documents, and none of the SEC Documents, at the time they were filed with the
            SEC, contained any untrue statement of a material fact or omitted to state a material
            fact required to be stated therein or necessary in order to make the statements
            therein, in the light of the circumstances under which they were made, not misleading.
            As of their respective dates, the financial statements of the Company included in the
            SEC Documents complied as to form in all material respects with applicable accounting
            requirements and the published rules and regulations of the SEC with respect thereto.
            Such financial statements have been prepared in accordance with generally accepted
            accounting principles, consistently applied, during the periods involved (except (i) as
            may be otherwise indicated in such financial statements or the notes thereto, or (ii)
            in the case of unaudited interim statements, to the extent they may exclude footnotes
            or may be condensed or summary statements) and fairly present in all material respects
            the financial position of the Company as of the dates thereof and the results of its
            operations and cash flows for the periods then ended (subject, in the case of unaudited
            statements, to normal year-end audit adjustments). No other information provided by or
            on behalf of the Company to the Buyers which is not included in the SEC Documents,
            including, without limitation, information referred to in Section 2(d) of this
            Agreement, contains any untrue statement of a material fact or omits to state any
            material fact necessary in order to make the statements therein, in the light of the
            circumstance under which they are or were made, not misleading.

            

            -9-

            
            
            

            
            

            

                
                      (l)       
            Absence of Certain Changes. Except as disclosed in Schedule 3(l), since June
            30, 2006, there has been no material adverse change and no material adverse development
            in the business, properties, operations, condition (financial or otherwise), results of
            operations or prospects of the Company or its Subsidiaries. Except as disclosed in
            Schedule 3(l), since June 30, 2006, the Company has not (i) declared or paid any
            dividends, (ii) sold any assets, individually or in the aggregate, in excess of
            $100,000 outside of the ordinary course of business or (iii) had capital expenditures,
            individually or in the aggregate, in excess of $100,000. Neither the Company nor any of
            its Subsidiaries has taken any steps to seek protection pursuant to any bankruptcy law
            nor does the Company have any knowledge or reason to believe that its creditors intend
            to initiate involuntary bankruptcy proceedings or any actual knowledge of any fact
            which would reasonably lead a creditor to do so. The Company is not as of the date
            hereof, and after giving effect to the transactions contemplated hereby to occur at the
            Closing, will not be Insolvent (as defined below). For purposes of this Section 3(l),
            “Insolvent” means, with respect to any Person (as defined in Section
            3(s), (i) the present fair saleable value of such Person’s assets is less than
            the amount required to pay such Person’s total Indebtedness (as defined in
            Section 3(s)), (ii) such Person is unable to pay its debts and liabilities,
            subordinated, contingent or otherwise, as such debts and liabilities become absolute
            and matured, (iii) the Company intends to incur or believes that it will incur debts
            that would be beyond its ability to pay as such debts mature or (iv) such Person has
            unreasonably small capital with which to conduct the business in which it is engaged as
            such business is now conducted and is proposed to be conducted.

            

                
                      (m)       
            No Undisclosed Events, Liabilities, Developments or Circumstances. No event,
            liability, development or circumstance has occurred or exists, or is contemplated to
            occur with respect to the Company, its Subsidiaries or their respective business,
            properties, prospects, operations or financial condition, that would be required to be
            disclosed by the Company under applicable securities laws on a registration statement
            on Form S-1 filed with the SEC relating to an issuance and sale by the Company of its
            Common Stock and which has not been publicly announced.

            

                
                      (n)       
            Conduct of Business; Regulatory Permits. Neither the Company nor its Subsidiaries
            is in violation of any term of or in default under any certificate of designations of
            any outstanding series of preferred stock of the Company, its Articles of Incorporation
            or Bylaws or their organizational charter or certificate of incorporation or bylaws,
            respectively. Neither the Company nor any of its Subsidiaries is in violation of any
            judgment, decree or order or any statute, ordinance, rule or regulation applicable to
            the Company or its Subsidiaries, and neither the Company nor any of its Subsidiaries
            will conduct its business in violation of any of the foregoing, except for possible
            violations which would not, individually or in the aggregate, have a Material Adverse
            Effect. Without limiting the generality of the foregoing, the Company is not in
            violation of any of the rules, regulations or requirements of the Principal Market and
            has no knowledge of any facts or circumstances which would reasonably lead to delisting
            or suspension of the Common Stock by the Principal Market in the foreseeable future.
            During the two years prior to the date hereof, the Common Stock has been designated for
            quotation on the Principal Market. During the two years prior to the date hereof, (i)
            trading in the Common Stock has not been suspended by the SEC or the Principal Market
            and (ii) the Company has received no communication, written or oral, from the SEC or
            the Principal Market regarding the suspension or delisting of the Common Stock from the
            Principal Market. The Company and its Subsidiaries possess all certificates,
            authorizations and permits issued by the appropriate regulatory authorities necessary
            to conduct their respective businesses, except where the failure to possess such
            certificates, authorizations or permits would not have, individually or in the
            aggregate, a Material Adverse Effect, and neither the Company nor any such Subsidiary
            has received any notice of proceedings relating to the revocation or modification of
            any such certificate, authorization or permit.

            

            -10-

            
            
            

            
            

            

                
                      (o)       
            Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor
            any director, officer, agent, employee or other Person acting on behalf of the Company
            or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the
            Company or any of its Subsidiaries (i) used any corporate funds for any unlawful
            contribution, gift, entertainment or other unlawful expenses relating to political
            activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic
            government official or employee from corporate funds; (iii) violated or is in violation
            of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv)
            made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful
            payment to any foreign or domestic government official or employee.

            

                
                      (p)       
            Sarbanes-Oxley Act. The Company is in compliance with any and all applicable
            requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date
            hereof, and any and all applicable rules and regulations promulgated by the SEC
            thereunder that are effective as of the date hereof.

            

                
                      (q)       
            Transactions With Affiliates. Except as set on Schedule 3(q), none of the
            officers, directors or employees of the Company is presently a party to any transaction
            with the Company or any of its Subsidiaries (other than for ordinary course services as
            employees, officers or directors), including any contract, agreement or other
            arrangement providing for the furnishing of services to or by, providing for rental of
            real or personal property to or from, or otherwise requiring payments to or from any
            such officer, director or employee or, to the knowledge of the Company or any of its
            Subsidiaries, any corporation, partnership, trust or other entity in which any such
            officer, director, or employee has a substantial interest or is an officer, director,
            trustee or partner.

            

                
                      (r)       
            Equity Capitalization. As of the date hereof, the authorized capital stock of the
            Company consists of (i) 100,000,000 shares of Common Stock, of which as of the date
            hereof, 44,089,995 are issued and outstanding, 8,200,000 shares are reserved for
            issuance pursuant to the Company’s stock option and purchase plans and no shares
            are reserved for issuance pursuant to securities (other than the aforementioned
            options, the Notes and the Warrants) exercisable or exchangeable for, or convertible
            into, shares of Common Stock and (ii) 20,000,000shares of preferred stock, par value
            $0.001 per share, of which as of the date hereof, none are issued and outstanding. All
            of such outstanding shares have been, or upon issuance will be, validly issued and are
            fully paid and nonassessable. Except as disclosed in Schedule 3(r): (i) none of
            the Company’s capital stock is subject to preemptive rights or any other similar
            rights or any liens or encumbrances suffered or permitted by the Company; (ii) there
            are no outstanding options, warrants, scrip, rights to subscribe to, calls or
            commitments of any character whatsoever relating to, or securities or rights
            convertible into, or exercisable or exchangeable for, any capital stock of the Company
            or any of its Subsidiaries, or contracts, commitments, understandings or arrangements
            by which the Company or any of its Subsidiaries is or may become bound to issue
            additional capital stock of the Company or any of its Subsidiaries or options,
            warrants, scrip, rights to subscribe to, calls or commitments of any character
            whatsoever relating to, or securities or rights convertible into, or exercisable or
            exchangeable for, any capital stock of the Company or any of its Subsidiaries; (iii)
            there are no outstanding debt securities, notes, credit agreements, credit facilities
            or other agreements, documents or instruments evidencing Indebtedness of the Company or
            any of its Subsidiaries or by which the Company or any of its Subsidiaries is or may
            become bound; (iv) there are no financing statements securing obligations in any
            material amounts, either singly or in the aggregate, filed in connection with the
            Company or any of its Subsidiaries; (v) there are no agreements or arrangements under
            which the Company or any of its Subsidiaries is obligated to register the sale of any
            of their securities under the 1933 Act (except pursuant to the Registration Rights
            Agreement); (vi) there are no outstanding securities or instruments of the Company or
            any of its Subsidiaries which contain any redemption or similar provisions, and there
            are no contracts, commitments, understandings or arrangements by which the Company or
            any of its Subsidiaries is or may become bound to redeem a security of the Company or
            any of its Subsidiaries; (vii) there are no securities or instruments containing
            anti-dilution or similar provisions that will be triggered by the issuance of the
            Securities; (viii) the Company does not have any stock appreciation rights or
            “phantom stock” plans or agreements or any similar plan or agreement; and
            (ix) the Company and its Subsidiaries have no liabilities or obligations required to be
            disclosed in the SEC Documents but not so disclosed in the SEC Documents, other than
            those incurred in the ordinary course of the Company’s or its Subsidiaries’
            respective businesses and which, individually or in the aggregate, do not or would not
            have a Material Adverse Effect. The Company has furnished to the Buyers true, correct
            and complete copies of the Company’s Articles of Incorporation, as amended and as
            in effect on the date hereof (the “Articles of Incorporation”), and
            the Company’s Bylaws, as amended and as in effect on the date hereof (the
            “Bylaws”), and the terms of all securities convertible into, or
            exercisable or exchangeable for, shares of Common Stock and the material rights of the
            holders thereof in respect thereto.

            

            -11-

            
            
            

            
            

            

                
                      (s)       
            Indebtedness and Other Contracts. Except as disclosed in Schedule 3(s),
            neither the Company nor any of its Subsidiaries (i) has any outstanding Indebtedness
            (as defined below), (ii) is a party to any contract, agreement or instrument, the
            violation of which, or default under which, by the other party(ies) to such contract,
            agreement or instrument would result in a Material Adverse Effect, (iii) is in
            violation of any term of or in default under any contract, agreement or instrument
            relating to any Indebtedness, except where such violations and defaults would not
            result, individually or in the aggregate, in a Material Adverse Effect, or (iv) is a
            party to any contract, agreement or instrument relating to any Indebtedness, the
            performance of which, in the judgment of the Company’s officers, has or is
            expected to have a Material Adverse Effect. Schedule 3(s) provides a detailed
            description of the material terms of any such outstanding Indebtedness. For purposes of
            this Agreement: (x) “Indebtedness” of any Person means, without
            duplication (A) all indebtedness for borrowed money, (B) all obligations issued,
            undertaken or assumed as the deferred purchase price of property or services, including
            (without limitation) “capital leases” in accordance with generally accepted
            accounting principles (other than trade payables entered into in the ordinary course of
            business), (C) all reimbursement or payment obligations with respect to letters of
            credit, surety bonds and other similar instruments, (D) all obligations evidenced by
            notes, bonds, debentures or similar instruments, including obligations so evidenced
            incurred in connection with the acquisition of property, assets or businesses, (E) all
            indebtedness created or arising under any conditional sale or other title retention
            agreement, or incurred as financing, in either case with respect to any property or
            assets acquired with the proceeds of such indebtedness (even though the rights and
            remedies of the seller or bank under such agreement in the event of default are limited
            to repossession or sale of such property), (F) all monetary obligations under any
            leasing or similar arrangement which, in connection with generally accepted accounting
            principles, consistently applied for the periods covered thereby, is classified as a
            capital lease, (G) all indebtedness referred to in clauses (A) through (F) above
            secured by (or for which the holder of such Indebtedness has an existing right,
            contingent or otherwise, to be secured by) any mortgage, lien, pledge, charge, security
            interest or other encumbrance upon or in any property or assets (including accounts and
            contract rights) owned by any Person, even though the Person which owns such assets or
            property has not assumed or become liable for the payment of such indebtedness, and (H)
            all Contingent Obligations in respect of indebtedness or obligations of others of the
            kinds referred to in clauses (A) through (G) above; (y) “Contingent
            Obligation” means, as to any Person, any direct or indirect liability,
            contingent or otherwise, of that Person with respect to any indebtedness, lease,
            dividend or other obligation of another Person if the primary purpose or intent of the
            Person incurring such liability, or the primary effect thereof, is to provide assurance
            to the obligee of such liability that such liability will be paid or discharged, or
            that any agreements relating thereto will be complied with, or that the holders of such
            liability will be protected (in whole or in part) against loss with respect thereto;
            and (z) “Person” means an individual, a limited liability company, a
            partnership, a joint venture, a corporation, a trust, an unincorporated organization
            and a government or any department or agency thereof.

            

            -12-

            
            
            

            
            

            

                
                      (t)       
            Absence of Litigation. There is no action, suit, proceeding, inquiry or
            investigation before or by the Principal Market, any court, public board, government
            agency, self-regulatory organization or body pending or, to the knowledge of the
            Company, threatened against or affecting the Company or any of its Subsidiaries, the
            Common Stock or any of the Company’s Subsidiaries or any of the Company’s
            or its Subsidiaries’ officers or directors in their capacities as such, except as
            set forth in Schedule 3(t).

            

                
                      (u)       
            Insurance. The Company and each of its Subsidiaries are insured by insurers of
            recognized financial responsibility against such losses and risks and in such amounts
            as management of the Company believes to be prudent and customary in the businesses in
            which the Company and its Subsidiaries are engaged. Neither the Company nor any such
            Subsidiary has been refused any insurance coverage sought or applied for and neither
            the Company nor any such Subsidiary has any reason to believe that it will not be able
            to renew its existing insurance coverage as and when such coverage expires or to obtain
            similar coverage from similar insurers as may be necessary to continue its business at
            a cost that would not have a Material Adverse Effect.

            

                
                      (v)       
            Employee Relations. (i) Neither the Company nor any of its Subsidiaries is a party
            to any collective bargaining agreement or employs any member of a union. The Company
            and its Subsidiaries believe that their relations with their employees are good. No
            executive officer of the Company or any of its Subsidiaries (as defined in Rule 501(f)
            of the 1933 Act) has notified the Company or any such Subsidiary that such officer
            intends to leave the Company or any such Subsidiary or otherwise terminate such
            officer’s employment with the Company or any such Subsidiary. No executive
            officer of the Company or any of its Subsidiaries, to the knowledge of the Company, is,
            or is now expected to be, in violation of any material term of any employment contract,
            confidentiality, disclosure or proprietary information agreement, non-competition
            agreement, or any other contract or agreement or any restrictive covenant, and the
            continued employment of each such executive officer does not subject the Company or any
            of its Subsidiaries to any liability with respect to any of the foregoing
            matters.

            

            -13-

            
            
            

            
            

            

                
                      
                      (ii)       The
            Company and its Subsidiaries are in compliance with all federal, state, local and
            foreign laws and regulations respecting labor, employment and employment practices and
            benefits, terms and conditions of employment and wages and hours, except where failure
            to be in compliance would not, either individually or in the aggregate, reasonably be
            expected to result in a Material Adverse Effect.

            

                
                      (w)       
            Title. The Company and its Subsidiaries have good and marketable title in fee
            simple to all real property and good and marketable title to all personal property
            owned by them which is material to the business of the Company and its Subsidiaries, in
            each case free and clear of all liens, encumbrances and defects except such as do not
            materially affect the value of such property and do not interfere with the use made and
            proposed to be made of such property by the Company and any of its Subsidiaries. Any
            real property and facilities held under lease by the Company and any of its
            Subsidiaries are held by them under valid, subsisting and enforceable leases with such
            exceptions as are not material and do not interfere with the use made and proposed to
            be made of such property and buildings by the Company and its Subsidiaries.

            

                
                      (x)       
            Intellectual Property Rights. The Company and its Subsidiaries own or possess
            adequate rights or licenses to use all trademarks, trade names, service marks, service
            mark registrations, service names, patents, patent rights, copyrights, inventions,
            licenses, approvals, governmental authorizations, trade secrets and other intellectual
            property rights (“Intellectual Property Rights”) necessary to
            conduct their respective businesses as now conducted. Except as set forth in
            Schedule 3(x), none of the Company’s Intellectual Property Rights have
            expired or terminated, or are expected to expire or terminate, within three years from
            the date of this Agreement. The Company does not have any knowledge of any infringement
            by the Company or its Subsidiaries of Intellectual Property Rights of others. There is
            no claim, action or proceeding being made or brought, or to the knowledge of the
            Company or its Subsidiaries, being threatened, against the Company or its Subsidiaries
            regarding its Intellectual Property Rights. The Company is unaware of any facts or
            circumstances which might give rise to any of the foregoing infringements or claims,
            actions or proceedings. The Company and its Subsidiaries have taken reasonable security
            measures to protect the secrecy, confidentiality and value of all of their intellectual
            properties.

            

                
                      (y)       
            Environmental Laws. The Company and its Subsidiaries (i) are in compliance with any
            and all Environmental Laws (as hereinafter defined), (ii) have received all permits,
            licenses or other approvals required of them under applicable Environmental Laws to
            conduct their respective businesses and (iii) are in compliance with all terms and
            conditions of any such permit, license or approval where, in each of the foregoing
            clauses (i), (ii) and (iii), the failure to so comply could be reasonably expected to
            have, individually or in the aggregate, a Material Adverse Effect. The term
            “Environmental Laws” means all federal, state, local or foreign laws
            relating to pollution or protection of human health or the environment (including,
            without limitation, ambient air, surface water, groundwater, land surface or subsurface
            strata), including, without limitation, laws relating to emissions, discharges,
            releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
            hazardous substances or wastes (collectively, “Hazardous
            Materials”)into the environment, or otherwise relating to the manufacture,
            processing, distribution, use, treatment, storage, disposal, transport or handling of
            Hazardous Materials, as well as all authorizations, codes, decrees, demands or demand
            letters, injunctions, judgments, licenses, notices or notice letters, orders, permits,
            plans or regulations issued, entered, promulgated or approved thereunder.

            

            -14-

            
            
            

            
            

            

                
                      (z)       
            Subsidiary Rights. Except as set forth in Schedule 3(z), the Company or one
            of its Subsidiaries has the unrestricted right to vote, and (subject to limitations
            imposed by applicable law) to receive dividends and distributions on, all capital
            securities of its Subsidiaries as owned by the Company or such Subsidiary.

            

                
                      (aa)       
            Investment Company Status. The Company is not, and upon consummation of the sale of
            the Securities will not be, an “investment company,” a company controlled
            by an “investment company” or an “affiliated person” of, or
            “promoter” or “principal underwriter” for, an “investment
            company” as such terms are defined in the Investment Company Act of 1940, as
            amended.

            

                
                      (bb)       
            Tax Status. The Company and each of its Subsidiaries (i) has made or filed all
            foreign, federal and state income and all other tax returns, reports and declarations
            required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
            governmental assessments and charges that are material in amount, shown or determined
            to be due on such returns, reports and declarations, except those being contested in
            good faith and (iii) has set aside on its books provision reasonably adequate for the
            payment of all taxes for periods subsequent to the periods to which such returns,
            reports or declarations apply. There are no unpaid taxes in any material amount claimed
            to be due by the taxing authority of any jurisdiction, and the officers of the Company
            know of no basis for any such claim.

            

                
                      (cc)       
            Internal Accounting and Disclosure Controls. The Company and each of its
            Subsidiaries maintain a system of internal accounting controls sufficient to provide
            reasonable assurance that (i) transactions are executed in accordance with
            management’s general or specific authorizations, (ii) transactions are recorded
            as necessary to permit preparation of financial statements in conformity with generally
            accepted accounting principles and to maintain asset and liability accountability,
            (iii) access to assets or incurrence of liabilities is permitted only in accordance
            with management’s general or specific authorization and (iv) the recorded
            accountability for assets and liabilities is compared with the existing assets and
            liabilities at reasonable intervals and appropriate action is taken with respect to any
            difference. The Company maintains disclosure controls and procedures (as such term is
            defined in Rule 13a-14 under the 1934 Act) that are effective in ensuring that
            information required to be disclosed by the Company in the reports that it files or
            submits under the 1934 Act is recorded, processed, summarized and reported, within the
            time periods specified in the rules and forms of the SEC, including, without
            limitation, controls and procedures designed in to ensure that information required to
            be disclosed by the Company in the reports that it files or submits under the 1934 Act
            is accumulated and communicated to the Company’s management, including its
            principal executive officer or officers and its principal financial officer or
            officers, as appropriate, to allow timely decisions regarding required disclosure.
            During the twelve months prior to the date hereof neither the Company nor any of its
            Subsidiaries have received any notice or correspondence from any accountant relating to
            any material weakness in any part of the system of internal accounting controls of the
            Company or any of its Subsidiaries

            

            -15-

            
            
            

            
            

            

            
                (dd)       
            Off Balance Sheet Arrangements. There is no transaction, arrangement, or other
            relationship between the Company and an unconsolidated or other off balance sheet
            entity that is required to be disclosed by the Company in its Exchange Act filings and
            is not so disclosed or that otherwise would be reasonably likely to have a Material
            Adverse Effect.

            

            
                (ee)       
            Ranking of Notes. Except as set forth on Schedule 3(ee), no Indebtedness of
            the Company is senior to or ranks pari passu with the Notes in right of payment,
            whether with respect of payment of redemptions, interest, damages or upon liquidation
            or dissolution or otherwise.

            

            
                (ff)       
            Form S-1 Eligibility. The Company is eligible to register the Conversion Shares,
            the Interest Shares and the Warrant Shares for resale by the Buyers using Form S-1
            promulgated under the 1933 Act.

            

            
                (gg)       
            Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than
            income or similar taxes) which are required to be paid in connection with the sale and
            transfer of the Securities to be sold to each Buyer hereunder will be, or will have
            been, fully paid or provided for by the Company, and all laws imposing such taxes will
            be or will have been complied with.

            

            
                (hh)       
            Manipulation of Price. The Company has not, and to its knowledge no one acting on
            its behalf has, (i) taken, directly or indirectly, any action designed to cause or to
            result in the stabilization or manipulation of the price of any security of the Company
            to facilitate the sale or resale of any of the Securities, (ii) other than the
            Placement Agent, sold, bid for, purchased, or paid any compensation for soliciting
            purchases of, any of the Securities, or (iii) other than the Placement Agent, paid or
            agreed to pay to any person any compensation for soliciting another to purchase any
            other securities of the Company.

            

            
                (ii)       
            Acknowledgement Regarding Buyers’ Trading Activity. It is understood and
            acknowledged by the Company that (i) none of the Buyers have been asked to agree, nor
            has any Buyer agreed, to desist from purchasing or selling, long and/or short,
            securities of the Company, or “derivative” securities based on securities
            issued by the Company or to hold the Securities for any specified term; (ii) any Buyer,
            and counter parties in “derivative” transactions to which any such Buyer is
            a party, directly or indirectly, presently may have a “short” position in
            the Common Stock, and (iii) each Buyer shall not be deemed to have any affiliation with
            or control over any arm’s length counter-party in any “derivative”
            transaction. The Company further understands and acknowledges that one or more Buyers
            may engage in hedging and/or trading activities at various times during the period that
            the Securities are outstanding, including, without limitation, during the periods that
            the value of the Conversion Shares, the Warrant Shares, and any Interest Shares
            deliverable with respect to Securities are being determined and (b) such hedging and/or
            trading activities, if any, can reduce the value of the existing stockholders’
            equity interest in the Company both at and after the time the hedging and/or trading
            activities are being conducted. The Company acknowledges that such aforementioned
            hedging and/or trading activities do not constitute a breach of this Agreement, the
            Notes, the Warrants or any of the documents executed in connection herewith.

            

            -16-

            
            
            

            
            

            

                
                      (jj)       
            U.S. Real Property Holding Corporation. The Company is not, nor has ever been, a
            U.S. real property holding corporation within the meaning of Section 897 of the
            Internal Revenue Code of 1986, as amended, and the Company shall so certify upon
            Buyer’s request.

            

                
                      (kk)       
            Bank Holding Company Act. Neither the Company nor any of its Subsidiaries is
            subject to the Bank Holding Company Act of 1956, as amended (the
            “BHCA”) and to regulation by the Board of Governors of the Federal
            Reserve System (the “Federal Reserve”). Neither the Company nor any
            of its Subsidiaries or affiliates owns or controls, directly or indirectly, five
            percent (5%) or more of the outstanding shares of any class of voting securities or
            twenty-five (25%) or more of the total equity of a bank or any equity that is subject
            to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of
            its Subsidiaries or affiliates exercises a controlling influence over the management or
            policies of a bank or any entity that is subject to the BHCA and to regulation by the
            Federal Reserve.

            

                
                      (ll)       
            Disclosure. The Company confirms that neither it nor any other Person acting on its
            behalf has provided any of the Buyers or their agents or counsel with any information
            that constitutes or could reasonably be expected to constitute material, nonpublic
            information. The Company understands and confirms that each of the Buyers will rely on
            the foregoing representations in effecting transactions in securities of the Company.
            All disclosure provided to the Buyers regarding the Company, or any of its
            Subsidiaries, their business and the transactions contemplated hereby, including the
            Schedules to this Agreement, furnished by or on behalf of the Company is true and
            correct and does not contain any untrue statement of a material fact or omit to state
            any material fact necessary in order to make the statements made therein, in the light
            of the circumstances under which they were made, not misleading. Each press release
            issued by the Company or any of its Subsidiaries during the twelve (12) months
            preceding the date of this Agreement did not at the time of release contain any untrue
            statement of a material fact or omit to state a material fact required to be stated
            therein or necessary in order to make the statements therein, in the light of the
            circumstances under which they were made, not misleading. No event or circumstance has
            occurred or information exists with respect to the Company or any of its Subsidiaries
            or its or their business, properties, prospects, operations or financial conditions,
            which, under applicable law, rule or regulation, requires public disclosure or
            announcement by the Company but which has not been so publicly announced or
            disclosed.

            

            
                    4.
                   COVENANTS.

            

                
                      (a)       
            Best Efforts. Each party shall use its best efforts timely to satisfy each of the
            conditions to be satisfied by it as provided in Sections 6 and 7 of this
            Agreement.

            

                
                      (b)       
            Form D and Blue Sky. The Company agrees to file a Form D with respect to the
            Securities as required under Regulation D and to provide a copy thereof to each Buyer
            promptly after such filing. The Company shall, on or before the Closing Date, take such
            action as the Company shall reasonably determine is necessary in order to obtain an
            exemption for or to qualify the Securities for sale to the Buyers at the Closing
            pursuant to this Agreement under applicable securities or “Blue Sky” laws
            of the states of the United States (or to obtain an exemption from such qualification),
            and shall provide evidence of any such action so taken to the Buyers on or prior to the
            Closing Date. The Company shall make all filings and reports relating to the offer and
            sale of the Securities required under applicable securities or “Blue Sky”
            laws of the states of the United States following the Closing Date.

            

            -17-

            
            
            

            
            

            

                
                      (c)       
            Reporting Status. Until the date on which the Investors (as defined in the
            Registration Rights Agreement) shall have sold all the Conversion Shares, the Interest
            Shares and Warrant Sharesand none of the Notes orWarrants is outstanding (the
            “Reporting Period”), the Company shall timely file all reports
            required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not
            terminate its status as an issuer required to file reports under the 1934 Act even if
            the 1934 Act or the rules and regulations thereunder would permit such
            termination.

            

                
                      (d)       
            Use of Proceeds. The Company will use the proceeds from the sale of the Securities
            for general corporate and for working capital purposes and, except as set forth in
            Schedule 4(d), not for (i) the repayment of any outstanding Indebtedness of the
            Company or any of its Subsidiaries, (ii) the redemption or repurchase of any of its or
            its Subsidiaries’ equity securities or (iii) the settlement of any claims,
            actions or proceedings against the Company or any of its Subsidiaries.

            

                
                      (e)       
            Financial Information. The Company agrees to send the following to each Investor
            (as defined in the Registration Rights Agreement) during the Reporting Period (i)
            unless the following are filed with the SEC through EDGAR and are available to the
            public through the EDGAR system, within one (1) Business Day after the filing thereof
            with the SEC, a copy of its Annual Reports and Quarterly Reports on Form 10-K, 10-KSB,
            10-Q or 10-QSB, any interim reports or any consolidated balance sheets, income
            statements, stockholders’ equity statements and/or cash flow statements for any
            period other than annual, any Current Reports on Form 8-K and any registration
            statements (other than on Form S-8) or amendments filed pursuant to the 1933 Act, (ii)
            on the same day as the release thereof, facsimile or e-mailed copies of all press
            releases issued by the Company or any of its Subsidiaries, and (iii) copies of any
            notices and other information made available or given to the stockholders of the
            Company generally, contemporaneously with the making available or giving thereof to the
            stockholders. As used herein, “Business Day” means any day other
            than Saturday, Sunday or other day on which commercial banks in The City of New York
            are authorized or required by law to remain closed.

            

                
                      (f)       
            Listing. The Company shall promptly secure the listing of all of the Registrable
            Securities (as defined in the Registration Rights Agreement) upon each national
            securities exchange and automated quotation system, if any, upon which the Common Stock
            is then listed (subject to official notice of issuance) and shall maintain such listing
            of all Registrable Securities from time to time issuable under the terms of the
            Transaction Documents. The Company shall maintain the Common Stocks’
            authorization for quotation on the Principal Market. Neither the Company nor any of its
            Subsidiaries shall take any action which would be reasonably expected to result in the
            delisting or suspension of the Common Stock on the Principal Market. The Company shall
            pay all fees and expenses in connection with satisfying its obligations under this
            Section 4(f).

            

            -18-

            
            
            

            
            

            

                
                      (g)       
            Fees. The Company shall reimburse Castlerigg Master Investments Ltd. (a Buyer) or
            its designee(s) (in addition to any other expense amounts paid to any Buyer prior to
            the date of this Agreement) for all reasonable costs and expenses incurred in
            connection with the transactions contemplated by the Transaction Documents (including
            all reasonable legal fees and disbursements in connection therewith, documentation and
            implementation of the transactions contemplated by the Transaction Documents and due
            diligence in connection therewith), which amount shall be withheld by such Buyer from
            its Purchase Price at the Closing. The Company shall be responsible for the payment of
            any placement agent’s fees, financial advisory fees, or broker’s
            commissions (other than for Persons engaged by any Buyer) relating to or arising out of
            the transactions contemplated hereby, including, without limitation, any fees or
            commissions payable to the Placement Agent. The Company shall pay, and hold each Buyer
            harmless against, any liability, loss or expense (including, without limitation,
            reasonable attorney’s fees and out-of-pocket expenses) arising in connection with
            any claim relating to any such payment. Except as otherwise set forth in the
            Transaction Documents, each party to this Agreement shall bear its own expenses in
            connection with the sale of the Securities to the Buyers.

            

                
                      (h)       
            Pledge of Securities. The Company acknowledges and agrees that the Securities may
            be pledged by an Investor (as defined in the Registration Rights Agreement) in
            connection with a bona fide margin agreement or other loan or financing arrangement
            that is secured by the Securities. The pledge of Securities shall not be deemed to be a
            transfer, sale or assignment of the Securities hereunder, and no Investor effecting a
            pledge of Securities shall be required to provide the Company with any notice thereof
            or otherwise make any delivery to the Company pursuant to this Agreement or any other
            Transaction Document, including, without limitation, Section 2(f) hereof; provided that
            an Investor and its pledgee shall be required to comply with the provisions of Section
            2(f) hereof in order to effect a sale, transfer or assignment of Securities to such
            pledgee. The Company hereby agrees to execute and deliver such documentation as a
            pledgee of the Securities may reasonably request in connection with a pledge of the
            Securities to such pledgee by an Investor.

            

                
                      (i)       
            Disclosure of Transactions and Other Material Information. On or before 8:30 a.m.,
            New York City time, on the first Business Day following the date of this Agreement, the
            Company shall issue a press release and file a Current Report on Form 8-K describing
            the terms of the transactions contemplated by the Transaction Documents in the form
            required by the 1934 Act and attaching the material Transaction Documents (including,
            without limitation, this Agreement, the form of the Notes, the form of Warrant, the
            form the Registration Rights Agreement and the form of Security Documents as exhibits
            to such filing (including all attachments, the “8-K Filing”). From
            and after the filing of the 8-K Filing with the SEC, no Buyer shall be in possession of
            any material, nonpublic information received from the Company, any of its Subsidiaries
            or any of their respective officers, directors, employees or agents, that is not
            disclosed in the 8-K Filing. The Company shall not, and shall cause each of its
            Subsidiaries and its and each of their respective officers, directors, employees and
            agents, not to, provide any Buyer with any material, nonpublic information regarding
            the Company or any of its Subsidiaries from and after the filing of the 8-K Filing with
            the SEC without the express written consent of such Buyer. If a Buyer has, or believes
            it has, received any such material, nonpublic information regarding the Company or any
            of its Subsidiaries, it shall provide the Company with written notice thereof. The
            Company shall, within two (2) Trading Days (as defined in the Notes) of receipt of such
            notice, make public disclosure of such material, nonpublic information. In the event of
            a breach of the foregoing covenant by the Company, any of its Subsidiaries, or any of
            its or their respective officers, directors, employees and agents, in addition to any
            other remedy provided herein or in the Transaction Documents, a Buyer shall have the
            right to make a public disclosure, in the form of a press release, public advertisement
            or otherwise, of such material, nonpublic information without the prior approval by the
            Company, its Subsidiaries, or any of its or their respective officers, directors,
            employees or agents. No Buyer shall have any liability to the Company, its
            Subsidiaries, or any of its or their respective officers, directors, employees,
            stockholders or agents for any such disclosure. Subject to the foregoing, neither the
            Company, its Subsidiaries nor any Buyer shall issue any press releases or any other
            public statements with respect to the transactions contemplated hereby; provided,
            however, that the Company shall be entitled, without the prior approval of any Buyer,
            to make any press release or other public disclosure with respect to such transactions
            (i) in substantial conformity with the 8-K Filing and contemporaneously therewith and
            (ii) as is required by applicable law and regulations (provided that in the case of
            clause (i) each Buyer shall be consulted by the Company in connection with any such
            press release or other public disclosure prior to its release). Without the prior
            written consent of any applicable Buyer, neither the Company nor any of its
            Subsidiaries or affiliates shall disclose the name of such Buyer in any filing,
            announcement, release or otherwise.

            

            -19-

            
            
            

            
            

            

                
                      (i)       
            Restriction on Redemption and Cash Dividends. So long as any Notes are outstanding,
            the Company shall not, directly or indirectly, redeem, or declare or pay any cash
            dividend or distribution on, the Common Stock without the prior express written consent
            of the holders of Notes representing not less than a majority of the aggregate
            principal amount of the then outstanding Notes.

            

                
                      (j)       
            Additional Notes; Variable Securities; Dilutive Issuances. So long as any Buyer
            beneficially owns any Securities, the Company will not issue any Notes other than to
            the Buyers as contemplated hereby and the Company shall not issue any other securities
            that would cause a breach or default under the Notes. For so long as any Notes or
            Warrants remain outstanding, the Company shall not, in any manner, issue or sell any
            rights, warrants or options to subscribe for or purchase Common Stock or directly or
            indirectly convertible into or exchangeable or exercisable for Common Stock at a price
            which varies or may vary with the market price of the Common Stock, including by way of
            one or more reset(s) to any fixed price unless the conversion, exchange or exercise
            price of any such security cannot be less than the then applicable Conversion Price (as
            defined in the Notes) with respect to the Common Stock into which any Note is
            convertible or the then applicable Exercise Price (as defined in the Warrants) with
            respect to the Common Stock into which any Warrant is exercisable. For so long as any
            Notes or Warrants remain outstanding, the Company shall not, in any manner, enter into
            or affect any Dilutive Issuance (as defined in the Notes) if the effect of such
            Dilutive Issuance is to cause the Company to be required to issue upon conversion of
            any Note or exercise of any Warrant any shares of Common Stock in excess of that number
            of shares of Common Stock which the Company may issue upon conversion of the Notes and
            exercise of the Warrants without breaching the Company’s obligations under the
            rules or regulations of the Principal Market or any applicable Eligible Market (as
            defined in the Registration Rights Agreement).

            

                
                      (k)       
            Corporate Existence. So long as any Buyer beneficially owns any Securities, the
            Company shall not be party to any Fundamental Transaction (as defined in the Notes)
            unless the Company is in compliance with the applicable provisions governing
            Fundamental Transactions set forth in the Notes and the Warrants.

            

            -20-

            
            
            

            
            

            

                
                      (l)       
            Reservation of Shares. So long as any Buyer owns any Securities, the Company shall
            take all action necessary to at all times have authorized, and reserved for the purpose
            of issuance, no less than 130% of the sum of the number of shares of Common Stock
            issuable (i) as Interest Shares pursuant to the terms of the Notes, (ii) upon
            conversion of the Notes and (iii) upon exercise of the Warrants then outstanding
            (without taking into account any limitations on the conversion of the Notes or exercise
            of the Warrants set forth in the Notes and Warrants, respectively).

            

                
                      (m)       
            Conduct of Business. The business of the Company and its Subsidiaries shall not be
            conducted in violation of any law, ordinance or regulation of any governmental entity,
            except where such violations would not result, either individually or in the aggregate,
            in a Material Adverse Effect.

            

                
                      (n)       
            Additional Issuances of Securities.

            

            	
                    	
                        
                            (i)              For
                        purposes of this Section 4(n), the following definitions shall
                        apply.

                    

            

            

            	
                    	
                        
                            (1)       “
                        Convertible Securities” means any stock or securities (other than
                        Options) convertible into or exercisable or exchangeable for shares of
                        Common Stock.

                    

            

            

            	
                    	
                        
                            (2)       “
                        Options” means any rights, warrants or options to subscribe for
                        or purchase shares of Common Stock or Convertible Securities.

                    

            

            

            	
                    	
                        
                            (3)       “
                        Common Stock Equivalents” means, collectively, Options and
                        Convertible Securities.

                    

            

            

            	
                    	
                        
                            (ii)       From
                        the date hereof until the date when all Registrable Securities (as defined
                        in the Registration Rights Agreement) have been registered (the
                        “Trigger Date”), the Company will not, directly or
                        indirectly, file any registration statement with the SEC other than the
                        Registration Statement (as defined in the Registration Rights Agreement).
                        From the date hereof until the Trigger Date, the Company will not, (i)
                        directly or indirectly, offer, sell, grant any option to purchase, or
                        otherwise dispose of (or announce any offer, sale, grant or any option to
                        purchase or other disposition of) any of its or its Subsidiaries’
                        equity or equity equivalent securities, including without limitation any
                        debt, preferred stock or other instrument or security that is, at any time
                        during its life and under any circumstances, convertible into or
                        exchangeable or exercisable for shares of Common Stock or Common Stock
                        Equivalents (any such offer, sale, grant, disposition or announcement being
                        referred to as a “Subsequent Placement”) or (ii) be
                        party to any solicitations, negotiations or discussions with regard to the
                        foregoing.

                    

            

            

            	
                    	
                        
                            (iii)       From
                        the Trigger Date until the second anniversary of the Closing Date, the
                        Company will not, directly or indirectly, effect any Subsequent Placement
                        unless the Company shall have first complied with this Section
                        4(n)(iii).

                    

            

            

            -21-

            
            
            

            
            

            

            
                (1)       The
            Company shall deliver to each Buyer an irrevocable written notice
            (the “Offer Notice”) of any proposed or intended issuance or
            sale or exchange (the “Offer”) of the securities being offered
            (the “Offered Securities”) in a Subsequent Placement, which Offer
            Notice shall (w) identify and describe the Offered Securities, (x) describe the
            price and other terms upon which they are to be issued, sold or exchanged, and the
            number or amount of the Offered Securities to be issued, sold or exchanged,
            (y) identify the persons or entities (if known) to which or with which the Offered
            Securities are to be offered, issued, sold or exchanged and (z) offer to issue and sell
            to or exchange with such Buyers all of the Offered Securities, allocated among such
            Buyers (a) based on such Buyer’s pro rata portion of the aggregate principal
            amount of Notes purchased hereunder (the “Basic Amount”), and (b)
            with respect to each Buyer that elects to purchase its Basic Amount, any additional
            portion of the Offered Securities attributable to the Basic Amounts of other Buyers as
            such Buyer shall indicate it will purchase or acquire should the other Buyers subscribe
            for less than their Basic Amounts (the “Undersubscription
            Amount”), which process shall be repeated until the Buyers shall have an
            opportunity to subscribe for any remaining Undersubscription Amount.

            

            
                (2)       To
            accept an Offer, in whole or in part, such Buyer must deliver a written notice to the
            Company prior to the end of the tenth (10th) Business Day after such
            Buyer’s receipt of the Offer Notice (the “Offer
            Period”), setting forth the portion of such Buyer’s Basic Amount
            that such Buyer elects to purchase and, if such Buyer shall elect to purchase all of
            its Basic Amount, the Undersubscription Amount, if any, that such Buyer elects to
            purchase (in either case, the “Notice of Acceptance”). If the Basic
            Amounts subscribed for by all Buyers are less than the total of all of the Basic
            Amounts, then each Buyer who has set forth an Undersubscription Amount in its Notice of
            Acceptance shall be entitled to purchase, in addition to the Basic Amounts subscribed
            for, the Undersubscription Amount it has subscribed for; provided,
            however, that if the Undersubscription Amounts subscribed for exceed the
            difference between the total of all the Basic Amounts and the Basic Amounts subscribed
            for (the “Available Undersubscription Amount”), each Buyer
            who has subscribed for any Undersubscription Amount shall be entitled to purchase only
            that portion of the Available Undersubscription Amount as the Basic Amount of such
            Buyer bears to the total Basic Amounts of all Buyers that have subscribed for
            Undersubscription Amounts, subject to rounding by the Company to the extent its deems
            reasonably necessary. Notwithstanding anything to the contrary contained herein, if
            the Company desires to modify or amend the terms and conditions of the Offer
            prior to the expiration of the Offer Period, the Company may deliver to the
            Buyers a new Offer Notice and the Offer Period shall expire on the tenth (10th)
            Business Day after such Buyer’s receipt of such new Offer
            Notice.

            

            
                (3)       The
            Company shall have five (5) Business Days from the expiration of the Offer Period above
            to offer, issue, sell or exchange all or any part of such Offered Securities as to
            which a Notice of Acceptance has not been given by the Buyers (the “Refused
            Securities”), but only to the offerees described in the Offer Notice (if so
            described therein) and only upon terms and conditions (including, without limitation,
            unit prices and interest rates) that are not more favorable to the acquiring person or
            persons or less favorable to the Company than those set forth in the Offer Notice and
            (ii) to publicly announce (a) the execution of such Subsequent Placement Agreement, and
            (b) either (x) the consummation of the transactions contemplated by such Subsequent
            Placement Agreement or (y) the termination of such Subsequent Placement Agreement,
            which shall be filed with the SEC on a Current Report on Form 8-K with such Subsequent
            Placement Agreement and any documents contemplated therein filed as exhibits
            thereto.

            

            -22-

            
            
            

            
            

            

            
                (4)       In
            the event the Company shall propose to sell less than all the Refused Securities (any
            such sale to be in the manner and on the terms specified in Section 4(n)(iii)(3)
            above), then each Buyer may, at its sole option and in its sole discretion, reduce the
            number or amount of the Offered Securities specified in its Notice of Acceptance to an
            amount that shall be not less than the number or amount of the Offered Securities that
            such Buyer elected to purchase pursuant to Section 4(n)(iii)(2) above multiplied by a
            fraction, (i) the numerator of which shall be the number or amount of Offered
            Securities the Company actually proposes to issue, sell or exchange (including Offered
            Securities to be issued or sold to Buyers pursuant to Section 4(n)(iii)(3) above prior
            to such reduction) and (ii) the denominator of which shall be the original amount of
            the Offered Securities. In the event that any Buyer so elects to reduce the number or
            amount of Offered Securities specified in its Notice of Acceptance, the Company may not
            issue, sell or exchange more than the reduced number or amount of the Offered
            Securities unless and until such securities have again been offered to the Buyers in
            accordance with Section 4(n)(iii)(1) above.

            

            
                (5)       Upon
            the closing of the issuance, sale or exchange of all or less than all of the Refused
            Securities, the Buyers shall acquire from the Company, and the Company shall issue to
            the Buyers, the number or amount of Offered Securities specified in the Notices of
            Acceptance, as reduced pursuant to Section 4(n)(iii)(3) above if the Buyers have so
            elected, upon the terms and conditions specified in the Offer. The purchase by the
            Buyers of any Offered Securities is subject in all cases to the preparation, execution
            and delivery by the Company and the Buyers of a purchase agreement relating to such
            Offered Securities reasonably satisfactory in form and substance to the Buyers and
            their respective counsel.

            

            
                (6)       Any
            Offered Securities not acquired by the Buyers or other persons in accordance with
            Section 4(n)(iii)(3) above may not be issued, sold or exchanged until they are again
            offered to the Buyers under the procedures specified in this Agreement.

            

            
                (7)       The
            Company and the Buyers agree that if any Buyer elects to participate in the Offer, (x)
            neither the agreement regarding the Subsequent Placement (the “Subsequent
            Placement Agreement”) with respect to such Offer nor any other transaction
            documents related thereto (collectively, the “Subsequent Placement
            Documents”) shall include any term or provisions whereby any Buyer shall
            be required to agree to any restrictions in trading as to any securities of the Company
            owned by such Buyer prior to such Subsequent Placement, and (y) any registration rights
            set forth in such Subsequent Placement Documents shall be similar in all material
            respects to the registration rights contained in the Registration Rights
            Agreement.

            

            -23-

            
            
            

            
            

            

            
                (8)       Notwithstanding
            anything to the contrary in this Section 4(n) and unless otherwise agreed to by the
            Buyers, the Company shall either confirm in writing to the Buyers that the transaction
            with respect to the Subsequent Placement has been abandoned or shall publicly disclose
            its intention to issue the Offered Securities, in either case in such a manner such
            that the Buyers will not be in possession of material non-public information, by the
            fifteenth (15th) Business Day following delivery of the Offer Notice. If by
            the fifteenth (15th) following delivery of the Offer Notice no public
            disclosure regarding a transaction with respect to the Offered Securities has been
            made, and no notice regarding the abandonment of such transaction has been received by
            the Buyers, such transaction shall be deemed to have been abandoned and the Buyers
            shall not be deemed to be in possession of any material, non-public information with
            respect to the Company. Should the Company decide to pursue such transaction with
            respect to the Offered Securities, the Company shall provide each Buyer with another
            Offer Notice and each Buyer will again have the right of participation set forth in
            this Section 4(n)(iii). The Company shall not be permitted to deliver more than one
            such Offer Notice to the Buyers in any 60 day period.

            

                
                      (iv)       The
            restrictions contained in subsections (ii) and (iii) of this Section 4(n) shall not
            apply in connection with the issuance of any Excluded Securities (as defined in the
            Notes).

            

                
                      (v)       Each
            Buyer hereby (a) appoints Castlerigg Master Investments Ltd., as the collateral agent
            hereunder and under the other Security Documents (in such capacity, the
            “Collateral Agent”), and (b) authorizes the Collateral Agent (and
            its officers, directors, employees and agents) to take such action on such
            Buyer’s behalf in accordance with the terms hereof and thereof. The Collateral
            Agent shall not have, by reason hereof or any of the other Security Documents, a
            fiduciary relationship in respect of any Buyer. Neither the Collateral Agent nor any of
            its officers, directors, employees and agents shall have any liability to any Buyer for
            any action taken or omitted to be taken in connection hereof or any other Security
            Document except to the extent caused by its own gross negligence or willful misconduct,
            and each Buyer agrees to defend, protect, indemnify and hold harmless the Collateral
            Agent and all of its officers, directors, employees and agents (collectively, the
            “Indemnitees”) from and against any losses, damages, liabilities,
            obligations, penalties, actions, judgments, suits, fees, costs and expenses (including,
            without limitation, reasonable attorneys’ fees, costs and expenses) incurred by
            such Indemnitee, whether direct, indirect or consequential, arising from or in
            connection with the performance by such Indemnitee of the duties and obligations of
            Collateral Agent pursuant hereto or any of the Security Documents. The Collateral Agent
            shall not be required to exercise any discretion or take any action, but shall be
            required to act or to refrain from acting (and shall be fully protected in so acting or
            refraining from acting) upon the instructions of the holders of at least a majority in
            principal amount of the Notes then outstanding, and such instructions shall be binding
            upon all holders of Notes; provided, however, that the Collateral Agent
            shall not be required to take any action which, in the reasonable opinion of the Agent,
            exposes the Agent to liability or which is contrary to this Agreement or any other
            Transaction Document or applicable law.

            

                
                      
                      (1)       The
            Collateral Agent shall be entitled to rely upon any written notices, statements,
            certificates, orders or other documents or any telephone message believed by it in good
            faith to be genuine and correct and to have been signed, sent or made by the proper
            Person, and with respect to all matters pertaining to this Agreement or any of the
            other Transaction Documents and its duties hereunder or thereunder, upon advice of
            counsel selected by it.

            

            -24-

            
            
            

            
            

            

                
                      (vi)       The
            Collateral Agent may resign from the performance of all its functions and duties
            hereunder and under the Notes and the Security Documents at any time by giving at least
            ten (10) Business Days prior written notice to the Company and each holder of the
            Notes. Such resignation shall take effect upon the acceptance by a successor Collateral
            Agent of appointment as provided below. Upon any such notice of resignation, the
            holders of a majority of the outstanding principal under the Notes shall appoint a
            successor Collateral Agent. Upon the acceptance of the appointment as Collateral Agent,
            such successor Collateral Agent shall succeed to and become vested with all the rights,
            powers, privileges and duties of the retiring Collateral Agent, and the retiring
            Collateral Agent shall be discharged from its duties and obligations under this
            Agreement, the Notes and the other Security Documents. After any Collateral
            Agent’s resignation hereunder , the provisions of this Section 4(n) shall inure
            to its benefit. If a successor Collateral Agent shall not have been so appointed within
            said ten (10) Business Day period, the retiring Collateral Agent shall then appoint a
            successor Collateral Agent who shall serve until such time, if any, as the holders of a
            majority of the outstanding principal under the Notes appoint a successor Collateral
            Agent as provided above.

            

                
                      (o)       
            Closing Documents. On or prior to fourteen (14) calendar days after the Closing
            Date, the Company agrees to deliver, or cause to be delivered, to each Buyer and
            Schulte Roth & Zabel LLP executed copies of the Transaction Documents, Securities
            and other document required to be delivered to any party pursuant to Section 7
            hereof.

            

                
                      (p)       
            No Waiver of Lock-Up Agreements. The Company shall not amend, waive or modify any
            provision of any of the Lock-Up Agreements (as defined below).

            

            
                    5.
                  REGISTER; TRANSFER AGENT INSTRUCTIONS.

            

                
                      (a)       
            Register. The Company shall maintain at its principal executive offices (or such
            other office or agency of the Company as it may designate by notice to each holder of
            Securities), a register for the Notes and the Warrants in which the Company shall
            record the name and address of the Person in whose name the Notes andthe Warrants have
            been issued (including the name and address of each transferee), the principal amount
            of Notes held by such Person, the number of Conversion Shares issuable upon conversion
            of the Notes and Warrant Shares issuable upon exercise of the Warrants held by such
            Person. The Company shall keep the register open and available at all times during
            business hours for inspection of any Buyer or its legal representatives.

            

                
                      (b)       
            Transfer Agent Instructions. The Company shall issue irrevocable instructions to
            its transfer agent, and any subsequent transfer agent, to issue certificates or credit
            shares to the applicable balance accounts at The Depository Trust Company
            (“DTC”), registered in the name of each Buyer or its respective
            nominee(s), for the Conversion Shares, the Interest Shares and the Warrant Shares
            issued at the Closing or upon conversion of the Notes or exercise of the Warrants in
            such amounts as specified in such amounts as specified from time to time by each Buyer
            to the Company upon conversion of the Notes or exercise of the Warrants in the form of
            Exhibit H (the “Irrevocable Transfer Agent Instructions”).
            The Company warrants that no instruction other than the Irrevocable Transfer Agent
            Instructions referred to in this Section 5(b), and stop transfer instructions to give
            effect to Section 2(g) hereof, will be given by the Company to its transfer agent, and
            that the Securities shall otherwise be freely transferable on the books and records of
            the Company as and to the extent provided in this Agreement and the other Transaction
            Documents. If a Buyer effects a sale, assignment or transfer of the Securities in
            accordance with Section 2(f), the Company shall permit the transfer and shall promptly
            instruct its transfer agent to issue one or more certificates or credit shares to the
            applicable balance accounts at DTC in such name and in such denominations as specified
            by such Buyer to effect such sale, transfer or assignment. In the event that such sale,
            assignment or transfer involves Conversion Shares, Interest Shares or Warrant Shares
            sold, assigned or transferred pursuant to an effective registration statement or
            pursuant to Rule 144, the transfer agent shall issue such Securities to the Buyer,
            assignee or transferee, as the case may be, without any restrictive legend. The Company
            acknowledges that a breach by it of its obligations hereunder will cause irreparable
            harm to a Buyer. Accordingly, the Company acknowledges that the remedy at law for a
            breach of its obligations under this Section 5(b) will be inadequate and agrees, in the
            event of a breach or threatened breach by the Company of the provisions of this Section
            5(b), that a Buyer shall be entitled, in addition to all other available remedies, to
            an order and/or injunction restraining any breach and requiring immediate issuance and
            transfer, without the necessity of showing economic loss and without any bond or other
            security being required.

            

            -25-

            
            
            

            
            

            

            
                    6.
                   CONDITIONS TO THE COMPANY’S OBLIGATION TO
            SELL.

            

            
                    The
            obligation of the Company hereunder to issue and sell the Notes and the related
            Warrants to each Buyer at the Closing is subject to the satisfaction, at or before the
            Closing Date, of each of the following conditions, provided that these conditions are
            for the Company’s sole benefit and may be waived by the Company at any time in
            its sole discretion by providing each Buyer with prior written notice
            thereof:

            

                
                      (i)           
            Such Buyer shall have executed each of the Transaction Documents to which it is a party
            and delivered the same to the Company.

            

                
                      (ii)           
            Such Buyer and each other Buyer shall have delivered to the Company the Purchase Price
            (less, in the case of Castlerigg Master Investments Ltd., the amounts withheld pursuant
            to Section 4(g)) for the Notes and the related Warrants being purchased by such Buyer
            at the Closing by wire transfer of immediately available funds pursuant to the wire
            instructions provided by the Company.

            

                
                      (iii)           
            The representations and warranties of such Buyer shall be true and correct in all
            material respects as of the date when made and as of the Closing Date as though made at
            that time (except for representations and warranties that speak as of a specific date),
            and such Buyer shall have performed, satisfied and complied in all material respects
            with the covenants, agreements and conditions required by this Agreement to be
            performed, satisfied or complied with by such Buyer at or prior to the Closing
            Date.

            

            
                    7.
                   CONDITIONS TO EACH BUYER’S OBLIGATION TO
            PURCHASE.

            

            
                    The
            obligation of each Buyer hereunder to purchase the Notesand the related Warrants at the
            Closing is subject to the satisfaction, at or before the Closing Date, of each of the
            following conditions, provided that these conditions are for each Buyer’s sole
            benefit and may be waived by such Buyer at any time in its sole discretion by providing
            the Company with prior written notice thereof:

            

            -26-

            
            
            

            
            

            

                
                      (i)           
            The Company shall have duly executed and delivered to such Buyer (A) each of the
            Transaction Documents and, (B) the Notes (in such principal amounts as such Buyer shall
            request), being purchased by such Buyer at the Closing pursuant to this Agreement, and
            (C) the related Warrants (in such amounts as such Buyer shall request) being purchased
            by such Buyer at the Closing pursuant to this Agreement.

            

                
                      (ii)           
            Such Buyer shall have received the opinion of Dennis Brovarone, the Company’s
            outside counsel, dated as of the Closing Date, in substantially the form of
            Exhibit H attached hereto.

            

                
                      (iii)           
            The Company shall have delivered to such Buyer a copy of the Irrevocable Transfer Agent
            Instructions, in the form of Exhibit I attached hereto, which instructions
            shall have been delivered to and acknowledged in writing by the Company’s
            transfer agent.

            

                
                      (iv)           
            The Company shall have delivered to such Buyer a certificate evidencing the formation
            and good standing of the Company and each of its Subsidiaries in such entity’s
            jurisdiction of formation issued by the Secretary of State (or comparable office) of
            such jurisdiction, as of a date within 10 days of the Closing Date.

            

                
                      (v)           
            The Company shall have delivered to such Buyer a certificate evidencing the
            Company’s qualification as a foreign corporation and good standing issued by the
            Secretary of State (or comparable office) of each jurisdiction in which the Company
            conducts business, as of a date within 10 days of the Closing Date.

            

                
                      (vi)           
            The Company shall have delivered to such Buyer a certified copy of the Articles of
            Incorporation as certified by the Secretary of State of the State (or comparable office
            of Nevada within ten (10) days of the Closing Date.

            

                
                      (vii)           
            The Company shall have delivered to such Buyer a certificate, executed by the Secretary
            of the Company and dated as of the Closing Date, as to (i) the resolutions consistent
            with Section 3(b) as adopted by the Company’s Board of Directors in a form
            reasonably acceptable to such Buyer, (ii) the Articles of Incorporation and (iii) the
            Bylaws, each as in effect at the Closing, in the form attached hereto as
            Exhibit J.

            

                
                      (viii)           
            The representations and warranties of the Company shall be true and correct as of the
            date when made and as of the Closing Date as though made at that time (except for
            representations and warranties that speak as of a specific date) and the Company shall
            have performed, satisfied and complied in all respects with the covenants, agreements
            and conditions required by the Transaction Documents to be performed, satisfied or
            complied with by the Company at or prior to the Closing Date. Such Buyer shall have
            received a certificate, executed by the Chief Executive Officer of the Company, dated
            as of the Closing Date, to the foregoing effect and as to such other matters as may be
            reasonably requested by such Buyer in the form attached hereto as Exhibit
            K.

            

            -27-

            
            
            

            
            

            

                
                      (ix)           
            The Company shall have delivered to such Buyer a letter from the Company’s
            transfer agent certifying the number of shares of Common Stock outstanding as of a date
            within five days of the Closing Date.

            

                
                      (x)           
            The Common Stock (I) shall be designated for quotation or listed on the Principal
            Market and (II) shall not have been suspended, as of the Closing Date, by the SEC or
            the Principal Market from trading on the Principal Market nor shall suspension by the
            SEC or the Principal Market have been threatened, as of the Closing Date, either (A) in
            writing by the SEC or the Principal Market or (B) by falling below the minimum listing
            maintenance requirements of the Principal Market.

            

                
                      (xi)           
            The Company shall have obtained all governmental, regulatory or third party consents
            and approvals, if any, necessary for the sale of the Securities.

            

                
                      (xii)           
            In accordance with the terms of the Security Documents, the Company shall have
            delivered to the Collateral Agent (i) certificates representing the Subsidiaries’
            shares of capital stock, along with duly executed blank stock powers and (ii)
            appropriate financing statements on Form UCC-1 to be duly filed in such office or
            offices as may be necessary or, in the opinion of the Collateral Agent, desirable to
            perfect the security interests purported to be created by each Security
            Document.

            

                
                      (xiii)           
            Within six (6) Business Days prior to the Closing, the Company shall have delivered or
            caused to be delivered to each Buyer (A) certified copies of UCC search results,
            listing all effective financing statements which name as debtor the Company or any of
            its Subsidiaries filed in the prior five years to perfect an interest in any assets
            thereof, together with copies of such financing statements, none of which, except as
            otherwise agreed in writing by the Buyers, shall cover any of the Collateral (as
            defined in the Security Documents) and the results of searches for any tax lien and
            judgment lien filed against such Person or its property, which results, except as
            otherwise agreed to in writing by the Buyers shall not show any such Liens (as defined
            in the Security Documents); and (B) a perfection certificate, duly completed and
            executed by the Company and each of its Subsidiaries, in form and substance
            satisfactory to the Buyers.

            

                
                      (xiv)           
            Such Buyer shall have received lock-up agreements in the form attached hereto as
            Exhibit L (the “Lock-Up Agreements”, duly executed and delivered by
            each of Shlomie Stein, Regency Capital Investments, Merit Investments, Marty Silver,
            Ron Sparkman and David Skinner, Sr. and the Company, which limits the rights of such
            persons to sell or transfer Common Stock of the Company until the second anniversary of
            the Closing Date.

            

                
                      (xv)           
            Contemporaneously with the Closing, the Company shall have repaid all Indebtedness
            specified on Schedule 3(s) and all such Indebtedness shall have been cancelled and the
            Company shall have delivered to the Buyers proof, in a form reasonably satisfactory to
            the Buyers, of such repayment and of the cancellation of such Indebtedness.

            

                
                      (xvi)           
            The Company shall have executed and delivered to the Collateral Agent mortgage
            documentation reasonably satisfactory to the Collateral Asset on the property located
            at 8224 CR 245, Holmsville, Ohio 44633.

            

                
                      (xvii)           
            The Company shall have delivered to such Buyer such other documents relating to the
            transactions contemplated by this Agreement as such Buyer or its counsel may reasonably
            request.

            

            -28-

            
            
            

            
            

            

            
                8.           
            TERMINATION. In the event that the Closing shall not have occurred with respect to
            a Buyer on or before five (5) Business Days from the date hereof due to the
            Company’s or such Buyer’s failure to satisfy the conditions set forth in
            Sections 6 and 7 above (and the nonbreaching party’s failure to waive such
            unsatisfied condition(s)), the nonbreaching party shall have the option to terminate
            this Agreement with respect to such breaching party at the close of business on such
            date without liability of any party to any other party; PROVIDED, however, that
            if this Agreement is terminated pursuant to this Section 8, the Company shall remain
            obligated to reimburse the non-breaching Buyers for the expenses described in Section
            4(g) above.

            

            
                9.           
            MISCELLANEOUS.

            

                
                      (a)           
            Governing Law; Jurisdiction; Jury Trial. All questions concerning the construction,
            validity, enforcement and interpretation of this Agreement shall be governed by the
            internal laws of the State of New York, without giving effect to any choice of law or
            conflict of law provision or rule (whether of the State of New York or any other
            jurisdictions) that would cause the application of the laws of any jurisdictions other
            than the State of New York. Each party hereby irrevocably submits to the exclusive
            jurisdiction of the state and federal courts sitting in The City of New York, Borough
            of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
            or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
            waives, and agrees not to assert in any suit, action or proceeding, any claim that it
            is not personally subject to the jurisdiction of any such court, that such suit, action
            or proceeding is brought in an inconvenient forum or that the venue of such suit,
            action or proceeding is improper. Each party hereby irrevocably waives personal service
            of process and consents to process being served in any such suit, action or proceeding
            by mailing a copy thereof to such party at the address for such notices to it under
            this Agreement and agrees that such service shall constitute good and sufficient
            service of process and notice thereof. Nothing contained herein shall be deemed to
            limit in any way any right to serve process in any manner permitted by law. EACH
            PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A
            JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
            ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

            

                
                      (b)           
            Counterparts. This Agreement may be executed in two or more identical counterparts,
            all of which shall be considered one and the same agreement and shall become effective
            when counterparts have been signed by each party and delivered to the other party;
            provided that a facsimile signature shall be considered due execution and shall be
            binding upon the signatory thereto with the same force and effect as if the signature
            were an original, not a facsimile signature.

            

                
                      (c)           
            Headings. The headings of this Agreement are for convenience of reference and shall
            not form part of, or affect the interpretation of, this Agreement.

            

                
                      (d)           
            Severability. If any provision of this Agreement shall be invalid or unenforceable
            in any jurisdiction, such invalidity or unenforceability shall not affect the validity
            or enforceability of the remainder of this Agreement in that jurisdiction or the
            validity or enforceability of any provision of this Agreement in any other
            jurisdiction.

            

            -29-

            
            
            

            
            

            

                
                      (e)           
            Entire Agreement; Amendments. This Agreement and the other Transaction Documents
            supersede all other prior oral or written agreements between the Buyers, the Company,
            their affiliates and Persons acting on their behalf with respect to the matters
            discussed herein, and this Agreement, the other Transaction Documents and the
            instruments referenced herein and therein contain the entire understanding of the
            parties with respect to the matters covered herein and therein and, except as
            specifically set forth herein or therein, neither the Company nor any Buyer makes any
            representation, warranty, covenant or undertaking with respect to such matters. No
            provision of this Agreement may be amended other than by an instrument in writing
            signed by the Company and the holders of at least a majority of the aggregate number of
            Registrable Securities issued and issuable hereunder and under the Notes, and any
            amendment to this Agreement made in conformity with the provisions of this Section 9(e)
            shall be binding on all Buyers and holders of Securities, as applicable. No provision
            hereof may be waived other than by an instrument in writing signed by the party against
            whom enforcement is sought. No such amendment shall be effective to the extent that it
            applies to less than all of the holders of the applicable Securities then outstanding.
            No consideration shall be offered or paid to any Person to amend or consent to a waiver
            or modification of any provision of any of the Transaction Documents unless the same
            consideration also is offered to all of the parties to the Transaction Documents,
            holders of Notes or holders of the Warrants, as the case may be. The Company has not,
            directly or indirectly, made any agreements with any Buyers relating to the terms or
            conditions of the transactions contemplated by the Transaction Documents except as set
            forth in the Transaction Documents. Without limiting the foregoing, the Company
            confirms that, except as set forth in this Agreement, no Buyer has made any commitment
            or promise or has any other obligation to provide any financing to the Company or
            otherwise.

            

                
                      (f)           
            Notices. Any notices, consents, waivers or other communications required or
            permitted to be given under the terms of this Agreement must be in writing and will be
            deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon
            receipt, when sent by facsimile (provided confirmation of transmission is mechanically
            or electronically generated and kept on file by the sending party); or (iii) one
            Business Day after deposit with an overnight courier service, in each case properly
            addressed to the party to receive the same. The addresses and facsimile numbers for
            such communications shall be:

            	
                    	
                    
	
                    	If to the
                    Company:

                    

                             Amish Naturals, Inc.

                             6399 State Route 83

                             Holmesville, OH 44633

                             Telephone: (330)
                    677-0998

                             Facsimile: (330) 279
                    2415

                             Attention: David Skinner,
                    Sr., President 

            

            

            -30-

            
            
            

            
            

            	
                    	
                    
	
                    	With a copy
                    to:

                    

                             Dennis Brovarone,
                    Esq.

                             Attorney at Law

                             18 Mountain Laurel
                    Drive

                             Littleton, Colorado
                    80127

                             Telephone: (303)
                    466-4092

                             Facsimile: (303)
                    466-4826

                    

                    

                    

                    If to the Transfer Agent:

                    

                             Signature Stock Transfer,
                    Inc.

                             2301 Ohio Drive - Suite
                    100

                             Plano, Texas 75093

                             Telephone: (972)
                    612-4120

                             Facsimile: (972)
                    612-4122

                             Attention: Jason M.
                    Bogutski - President 

            

            

            If to a Buyer, to its address
            and facsimile number set forth on the Schedule of Buyers, with copies to such
            Buyer’s representatives as set forth on the Schedule of Buyers,

            	
                    	
                    
	
                    	with a copy
                    (for informational purposes only) to:

                    

                             Schulte Roth & Zabel
                    LLP

                             919 Third Avenue

                             New York, New York
                    10022

                             Telephone: (212)
                    756-2000

                             Facsimile: (212)
                    593-5955

                             Attention: Eleazer N.
                    Klein, Esq. 

            

            

            or to such other address and/or
            facsimile number and/or to the attention of such other Person as the recipient party
            has specified by written notice given to each other party five (5) days prior to the
            effectiveness of such change. Written confirmation of receipt (A) given by the
            recipient of such notice, consent, waiver or other communication, (B) mechanically or
            electronically generated by the sender’s facsimile machine containing the time,
            date, recipient facsimile number and an image of the first page of such transmission or
            (C) provided by an overnight courier service shall be rebuttable evidence of personal
            service, receipt by facsimile or receipt from an overnight courier service in
            accordance with clause (i), (ii) or (iii) above, respectively.

            

            
                      
                      (g)    
            Successors and Assigns. This Agreement shall be binding upon and inure to the
            benefit of the parties and their respective successors and assigns, including any
            purchasers of the Notes or the Warrants. The Company shall not assign this Agreement or
            any rights or obligations hereunder without the prior written consent of the holders of
            at least a majority of the aggregate number of Registrable Securities issued and
            issuable hereunder, including by way of a Fundamental Transaction (unless the Company
            is in compliance with the applicable provisions governing Fundamental Transactions set
            forth in the Notes and the Warrants). A Buyer may assign some or all of its rights
            hereunder without the consent of the Company, in which event such assignee shall be
            deemed to be a Buyer hereunder with respect to such assigned rights.

            

            -31-

            
            
            

            
            

            

            
                      
                      (h)    
            No Third Party Beneficiaries. This Agreement is intended for the benefit of the
            parties hereto and their respective permitted successors and assigns, and is not for
            the benefit of, nor may any provision hereof be enforced by, any other
            Person.

            

            
                      
                      (i)    
            Survival. Unless this Agreement is terminated under Section 8, the
            representations and warranties of the Company and the Buyers contained in Sections 2
            and 3, and the agreements and covenants set forth in Sections 4, 5 and 9 shall survive
            the Closing. Each Buyer shall be responsible only for its own representations,
            warranties, agreements and covenants hereunder.

            

            
                      
                      (j)    
            Further Assurances. Each party shall do and perform, or cause to be done and
            performed, all such further acts and things, and shall execute and deliver all such
            other agreements, certificates, instruments and documents, as any other party may
            reasonably request in order to carry out the intent and accomplish the purposes of this
            Agreement and the consummation of the transactions contemplated hereby.

            

            
                      
                      (k)    
            Indemnification. In consideration of each Buyer’s execution and delivery
            of the Transaction Documents and acquiring the Securities thereunder and in addition to
            all of the Company’s other obligations under the Transaction Documents, the
            Company shall defend, protect, indemnify and hold harmless each Buyer and each other
            holder of the Securities and all of their stockholders, partners, members, officers,
            directors, employees and direct or indirect investors and any of the foregoing
            Persons’ agents or other representatives (including, without limitation, those
            retained in connection with the transactions contemplated by this Agreement)
            (collectively, the “Indemnitees”) from and against any and all
            actions, causes of action, suits, claims, losses, costs, penalties, fees, liabilities
            and damages, and expenses in connection therewith (irrespective of whether any such
            Indemnitee is a party to the action for which indemnification hereunder is sought), and
            including reasonable attorneys’ fees and disbursements (the “Indemnified
            Liabilities”), incurred by any Indemnitee as a result of, or arising out of,
            or relating to (a) any misrepresentation or breach of any representation or warranty
            made by the Company in the Transaction Documents or any other certificate, instrument
            or document contemplated hereby or thereby, (b) any breach of any covenant, agreement
            or obligation of the Company contained in the Transaction Documents or any other
            certificate, instrument or document contemplated hereby or thereby or (c) any cause of
            action, suit or claim brought or made against such Indemnitee by a third party
            (including for these purposes a derivative action brought on behalf of the Company) and
            arising out of or resulting from (i) the execution, delivery, performance or
            enforcement of the Transaction Documents or any other certificate, instrument or
            document contemplated hereby or thereby, (ii) any transaction financed or to be
            financed in whole or in part, directly or indirectly, with the proceeds of the issuance
            of the Securities, (iii) any disclosure made by such Buyer pursuant to Section 4(i), or
            (iv) the status of such Buyer or holder of the Securities as an investor in the Company
            pursuant to the transactions contemplated by the Transaction Documents. To the extent
            that the foregoing undertaking by the Company may be unenforceable for any reason, the
            Company shall make the maximum contribution to the payment and satisfaction of each of
            the Indemnified Liabilities that is permissible under applicable law. Except as
            otherwise set forth herein, the mechanics and procedures with respect to the rights and
            obligations under this Section 9(k) shall be the same as those set forth in Section 6
            of the Registration Rights Agreement.

            

            -32-

            
            
            

            
            

            

            
                      
                      (l)    
            No Strict Construction. The language used in this Agreement will be deemed to be
            the language chosen by the parties to express their mutual intent, and no rules of
            strict construction will be applied against any party.

            

            
                      
                      (m)    
            Remedies. Each Buyer and each holder of the Securities shall have all rights and
            remedies set forth in the Transaction Documents and all rights and remedies which such
            holders have been granted at any time under any other agreement or contract and all of
            the rights which such holders have under any law. Any Person having any rights under
            any provision of this Agreement shall be entitled to enforce such rights specifically
            (without posting a bond or other security), to recover damages by reason of any breach
            of any provision of this Agreement and to exercise all other rights granted by law.
            Furthermore, the Company recognizes that in the event that it fails to perform,
            observe, or discharge any or all of its obligations under the Transaction Documents,
            any remedy at law may prove to be inadequate relief to the Buyers. The Company
            therefore agrees that the Buyers shall be entitled to seek temporary and permanent
            injunctive relief in any such case without the necessity of proving actual damages and
            without posting a bond or other security.

            

            
                      
                      (n)    
            Rescission and Withdrawal Right. Notwithstanding anything to the contrary
            contained in (and without limiting any similar provisions of) the Transaction
            Documents, whenever any Buyer exercises a right, election, demand or option under a
            Transaction Document and the Company does not timely perform its related obligations
            within the periods therein provided, then such Buyer may rescind or withdraw, in its
            sole discretion from time to time upon written notice to the Company, any relevant
            notice, demand or election in whole or in part without prejudice to its future actions
            and rights.

            

            
                      
                      (o)    
            Payment Set Aside. To the extent that the Company makes a payment or payments to
            the Buyers hereunder or pursuant to any of the other Transaction Documents or the
            Buyers enforce or exercise their rights hereunder or thereunder, and such payment or
            payments or the proceeds of such enforcement or exercise or any part thereof are
            subsequently invalidated, declared to be fraudulent or preferential, set aside,
            recovered from, disgorged by or are required to be refunded, repaid or otherwise
            restored to the Company, a trustee, receiver or any other Person under any law
            (including, without limitation, any bankruptcy law, foreign, state or federal law,
            common law or equitable cause of action), then to the extent of any such restoration
            the obligation or part thereof originally intended to be satisfied shall be revived and
            continued in full force and effect as if such payment had not been made or such
            enforcement or setoff had not occurred.

            

            --33-
            -

            
            
            

            
            

            

            
                      
                      (p)    
            Independent Nature of Buyers’ Obligations and Rights. The obligations of
            each Buyer under any Transaction Document are several and not joint with the
            obligations of any other Buyer, and no Buyer shall be responsible in any way for the
            performance of the obligations of any other Buyer under any Transaction Document.
            Nothing contained herein or in any other Transaction Document, and no action taken by
            any Buyer pursuant hereto or thereto, shall be deemed to constitute the Buyers as, and
            the Company acknowledges that the Buyers do not so constitute, a partnership, an
            association, a joint venture or any other kind of entity, or create a presumption that
            the Buyers are in any way acting in concert or as a group, and the Company will not
            assert any such claim with respect to such obligations or the transactions contemplated
            by the Transaction Documents and the Company acknowledges that the Buyers are not
            acting in concert or as a group with respect to such obligations or the transactions
            contemplated by the Transaction Documents. The Company acknowledges and each Buyer
            confirms that it has independently participated in the negotiation of the transaction
            contemplated hereby with the advice of its own counsel and advisors. Each Buyer shall
            be entitled to independently protect and enforce its rights, including, without
            limitation, the rights arising out of this Agreement or out of any other Transaction
            Documents, and it shall not be necessary for any other Buyer to be joined as an
            additional party in any proceeding for such purpose.

            

            [Signature Page
            Follows]

            

            

            

            

            

            

            -34-

            
            

            
            

            

            
                    
            IN WITNESS WHEREOF, each Buyer and the Company have caused their respective
            signature page to this Securities Purchase Agreement to be duly executed as of the date
            first written above.

            	
                    	
                    
	
                    	
                    COMPANY:

                    

                    AMISH NATURALS, INC.

                    

                    

                    

                    

                    By:       /s/ Troy Trenengan

                           Name: Troy Trenengan

                           Title: Executive Vice
                    -President 

            

            

            

            

            

            

            

            -35-

            
            

            
            

            

            
                    
            IN WITNESS WHEREOF, each Buyer and the Company have caused their respective
            signature page to this Securities Purchase Agreement to be duly executed as of the date
            first written above.

            	
                    	
                    
	
                    	BUYER:

                    

                    CASTLERIGG MASTER INVESTMENTS LTD.

                    

                    BY: SANDELL ASSET MANAGEMENT CORP.

                    

                    By: /s/ RICHARD GASHLER

                           Name: RICHAR GASHLER

                           Title: GENERAL COUNSEL 

            

            

            

            

            

            

            -36-

            
            

            
            

            

            SCHEDULE OF
            BUYERS

            	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	
                        Buyer
                        

                    	
                        Address and

                        Facsimile Number
                        

                    	
                        Aggregate

                        Principal

                        Amount of

                        Notes
                        

                    	
                        Number of

                        Series A

                        Warrant Shares
                        

                    	
                        Number of

                        Series B

                        Warrant Shares
                        

                    	
                        Number of

                        Series C

                        Warrant Shares
                        

                    	
                        Number of

                        Series D

                        Warrant Shares
                        

                    	
                        Initial Purchase

                        Price
                        

                    	
                        Legal Representative's
                        Address and Facsimile Number
                        

                    
	Castlerigg
                    Master

                    Investments Ltd. 	c/o Sandell
                    Asset Management

                    40 West 57th St

                    26th Floor

                    New York, NY 10019

                    Attention: Cem

                    Hacioglu/Matthew Pliskin

                    Fax: 212-603-5710

                    Telephone: 212-603-5700

                    Residence: British Virgin

                    Islands 	
                    $6,000,000 	
                    1,597,331 	
                    798,665 	
                    798,665 	
                    3,194,661 	
                    $6,000,000 	Schulte
                    Roth & Zabel LLP

                    919 Third Avenue

                    New York, New York 10022

                    Attention: Eleazer Klein, Esq.

                    Facsimile: (212) 593-5955

                    Telephone: (212) 756-2376 
	
                    	
                    	
                    	
                    	
                    	
                    	
                    	
                    	
                    

            

            

            
            

            
            

            

            
            EXHIBITS

            	
                    	
                    
	Exhibit
                    A

                    Exhibit B

                    Exhibit C

                    Exhibit D

                    Exhibit E

                    Exhibit F

                    Exhibit G

                    Exhibit H

                    Exhibit I

                    Exhibit J

                    Exhibit K

                    Exhibit L 	Form of
                    Notes

                    Form of Series A, B and C Warrants

                    Form of Series D Warrants

                    Form of Registration Rights Agreement

                    Form of Pledge Agreement

                    Form of Security Agreement

                    Form of Guaranty

                    Form of Irrevocable Transfer Agent Instructions

                    Form of Opinion of Company's Counsel

                    Form of Secretary's Certificate

                    Form of Officer's Certificate

                    Form of Lock-Up Agreement 

            

            

            
            SCHEDULES

            	
                    	
                    
	Schedule
                    3(a)

                    Schedule 3(k)

                    Schedule 3(l)

                    Schedule 3(q)

                    Schedule 3(r)

                    Schedule 3(s)

                    Schedule 3(t)

                    Schedule 3(x)

                    Schedule 3(z)

                    Schedule 3(ee)

                    Schedule 4(d) 	
                    Subsidiaries

                    SEC Documents

                    Absence of Certain Changes

                    Transactions with Affiliates

                    Equity Capitalization

                    Indebtedness and Other Contracts

                    Absence of Litigation

                    Intellectual Property Rights

                    Subsidiary Rights

                    Ranking of Notes

                    Use of Proceeds

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]